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Abstract
Carcinogenesis is commonly described as a multistage process. In a first
step, a stem cell is transformed via a series of mutations into an inter-
mediate cell having a growth advantage. Under favorable conditions,
such a cell will give rise to a clone of initiated cells. Eventually, fur-
ther alterations may transform a cell out of this clone into a malignant
tumor cell.
A mechanistic model of this process is given by the widely used
two-stage clonal expansion model (TSCE). In this thesis, we take up a
generalization of the TSCE, and study, how to introduce the concept
of population heterogeneity into the model. We use mixture modeling,
which allows to describe frailty in a biologically meaningful way.
In a first part, we focus on theoretical properties of the extended
model. Especially identifiability is discussed extensively. In a second
part, we fit the model to human cancer incidence data. We analyze a
situation, in which maximum likelihood estimation fails, and describe
alternatives for statistical inference. The applications show that good
fits are achieved only when the mixing distribution separates the pop-
ulation clearly into a large, virtually immune group, and into a small,
high risk group.
Keywords: Multistage carcinogenesis; Heterogeneity; Frailty modeling;
Mixture modeling

Version Abrégée
De manière générale, la carcinogénèse est décrite comme un processus
à étapes multiples. Dans une première phase, une cellule souche subit
des mutations qui ont l’effet de lui donner la capacité d’une croissance
accélérée. Sous des conditions favorables, une telle cellule donnera lieu
à un clone de cellules initiées. Dans une deuxième phase, une cellule
initiée est transformée en cellule de cancer.
Le modèle à deux étapes avec expansion clonale (DEEC) est un
modèle méchaniste souvent utilisé pour modéliser la carcinogénèse. Le
but de cette thèse consiste à introduire la notion d’hétérogénéité dans
le modèle DEEC. On va utiliser les modèles mélangés à cette fin. Cette
méthodologie nous donne la possibilité d’introduire la notion de fragilité
d’une manière à avoir un sens biologique.
Nous discutons d’abord les propriétés théoriques du modèle. En
particulier, nous étudions en détail l’identifiabilité. Ensuite, nous mon-
trons des applications du modèle à des données d’incidence chez l’homme.
Nous sommes confrontés à une situation, dans laquelle l’estimation par
maximum de vraisemblance échoue, ce qui nous amène à proposer des
alternatives. Les applications suggèrent une population qui consiste de
deux groupes, dont un est à risque très bas.
Mots clés: Carcinogénèse; Modèle à étapes multiples; Hétérogénéité;
Modèles de fragilité; Modèles mélangés
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CHAPTER 1
Introduction
Sadly, we are all familiar with cancer. In the more developed countries,
it is the second leading cause of death behind cardiovascular disease.
But it aﬄicts all communities worldwide. We are all confronted with
cancer either directly, as a patient, a friend or a relative of a patient, or
indirectly, through campaigns and debates. And although prevention
and treatment do show successes, the burden of cancer will tend to
increase in countries, in which the age structure of the population shifts
towards a larger proportion of older people.
This thesis is situated in the field of mathematical cancer research.
We work with a class of carcinogenesis models that are based on bio-
logical theory. The reader need not be frightened, however, because we
start with a short introduction to cancer biology, and will also review
some statistical methodology that will be used extensively later on.
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1.1 Basic Cancer Biology
The term cancer does not stand for a single disease, but represents a
collection of diseases characterized by uncontrolled cell proliferation.
Cells that would be quiescent in their normal state continue cell divi-
sion, form clones, eventually invade surrounding tissues and metastasize
to other parts of the body through blood vessels or lymphatic channels.
A short list of basic definitions that will be used extensively in this text
is as follows:
Tumor General term for an uncontrolled growth of cells.
Neoplasm Same as tumor.
Benign tumor A tumor that does not metastasize or invade sur-
rounding tissues.
Malignant tumor A tumor that has the ability to metastasize or
invade surrounding tissues.
Cancer Same as malignant tumor.
Metastasis Ability to establish secondary tumor growth at a new lo-
cation in the body away from original site.
Carcinogenesis Formation of a carcinoma. Or: General term for the
formation of any type of cancer.
Cancer can arise in virtually any tissue. But it is much more likely
to develop in frequently renewing cells, like epithelial cells, than in parts
of the body that do not normally proliferate, like neurons. Malignant
tumors can be classified according to their tissue type of origin. Carci-
nomas, the most common form of cancer, arise in epithelium (sheets of
tightly packed cells that line organs and body cavities). Sarcomas arise
in connective or muscle tissues. Leukemia and lymphoma are malig-
nant tumors of the hematopoietic system, the blood forming structure
of the body, and have no benign counterparts.
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The term carcinogenesis is used in two different ways. The first
one refers to the production of a carcinoma (epithelial cancer). The
second one means the general process leading to any type of tumor.
Throughout this text, we will refer to the latter meaning, when talking
about carcinogenesis.
Although clinically cancer is a large group of diseases that vary in
age of onset, growth rate, invasiveness, potential to form metastasis,
treatability, etc., the molecular and cellular mechanisms that lead to
cancer remain similar for most cancer types. For general accounts on
cancer biology see for example Ruddon (1995); Franks and Teich (2001).
See Weinberg (1996) for a general review of carcinogenesis, our next
topic.
The normal, healthy body of an adult consists of more than 1013
cells. Some organs, like the skin, are renewed constantly while others
renew very slowly. Regulation of cell proliferation is therefore a complex
and crucial mechanism for the stable functioning of the body. Normal
cells divide only when instructed to do so. Tumor cells violate this rule.
They either proliferate without stimulation by external signals, or they
become deaf to inhibitory factors.
Cancer is a genetic disease. The failure of cell cycle control is caused
by mutations in certain groups of genes and several events are needed
to transform a normal cell into a tumor. Proto-oncogenes code for
proteins that stimulate cell division (mitosis). In mutated forms, called
oncogenes, they overexpress these proteins leading to excessive cell pro-
liferation. Their counterparts are tumor suppressors: genes which in-
hibit mitosis. Neighbouring cells of a non-normal dividing cell will send
"stop" signals to activate those genes. Mutations in tumor suppressor
genes can cause break-down of this control. A further backup system
consists in programmed cell death (apoptosis). If essential parts of a
cell get damaged, a signal to commit suicide is sent. Cancer cells escape
also from this program. A final control mechanism is cell ageing (see
Mathon and Lloyd (2001)). In normal cells specific DNA segments,
called telomeres, at chromosome ends shorten a bit at every cell divi-
sion. This molecular counting device is used to instruct the cell after
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an intrinsically defined number of doublings to stop growth and enter
into a senescent state. Cancer cells on the contrary systematically re-
place the telomeric segments cut off at each cell cycle. Their telomeres
remain intact and cells reach immortality. A related topic is stem cell
biology, which is important for therapy development. See for example
Pardal et al. (2003); Jones et al. (2004).
Hallmarks of malignancy are invasiveness and ability to metasta-
size. A primary tumor (of immortal cells) can often relatively easily
be removed surgically. But the spread of malignant cells all over the
body is what makes cancer so lethal. Normal cells have structures on
their surface that identify where in the body the cell should be. Such
area codes mediate cell-cell adhesion and anchorage of tissues to adja-
cent structures. In cancer, genetic events have caused this system to
go wrong (a review of cancer spread is given by Ruoslahti (1996)).
The origin of a cancer is monoclonal. A single cell can give rise
to a malignant tumor through an evolutionary process. A sequence
of mutations transforms a stem cell into a so-called initiated cell hav-
ing the potential of a growth advantage. Under favorable conditions,
the initiated cell will give rise to a clonal expansion. Proliferation of
such initiated cells is facilitated by site specific promoters and may
even depend completely on the presence of such agents. Examples are
hormones, anabolic steroids, but also salt or tobacco. Further changes
transform a cell out of this clone into a malignant tumor cell. Ge-
netic and epigenetic events are involved in this step. The process of
carcinogenesis is drawn schematically in Figure 1.
Such an initiation-promotion pattern holds for most cancer types,
though the number and type of mutations involved is site specific (see
Knudson (2001)). When talking about the number of mutations needed
to cause cancer, what we are really interested in is the number of rate
limiting events. Malignant cells show thousands of mutations that are
an effect but not a cause of cancer. The role of genomic instability in
the transformation of a normal cell into a cancer cell is part of ongoing
debate. Many cancers show chromosomal instability, that means an
increased rate of loss or gain of whole chromosome parts during cell di-
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Normal cell Initiated cell Preneoplastic lesion Tumor cell Cancer Metastasis
Figure 1: Evolution of a normal stem cell into a cancer cell. Mutations lead
to an initiated cell, which gives rise to a pre-neoplastic clone. A cell out of this
clone may mutate further and generate a clinically detectable cancer. Finally,
cancer cells spread through the body and form distant malignant clones.
vision. This might for example accelerate the rate of tumor suppressor
gene inactivation and thereby reduce the number of rate limiting steps
required (see Tomlinson et al. (2002); Michor et al. (2004)).
A consequence of this theory is that carcinogenesis is intrinsically a
random process. But the probability to develop cancer varies consid-
erably among individuals. This is due to inherited factors as well as to
different exposure to environmental and industrial carcinogens. Since
cancer is caused by mutations, carcinogenic is basically anything that
is mutagenic and anything that stimulates the rate of mitosis. Lifestyle
is a major cause, the most prominent lifestyle factors being diet and
tobacco use. Finally, the development of cancer can be initiated by
other elements like certain viruses or chronic inflammation.
Mutations are rare events - at least in a healthy body under normal
environmental conditions. Since carcinogenesis requires multiple mu-
tations, the waiting time for tumor onset is generally several decades.
Therefore, cancer is mainly a disease of older age groups. Still child-
hood cancer does occur. Many of such cases are explained by inherited
mutations in cancer causing genes. If mutations occur in the germ line
of a parent, the defective gene may be passed to the next generation.
The offspring starts life with all cells in some intermediate stage. In
the worst case a single mutation could be enough to cause cancer.
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1.2 Mathematical Cancer Research
Quantitative applications can be found in many fields related to can-
cer research, and the mathematical tools used vary considerably. We
give here a short overview of some selected topics with no claim of
completeness.
An important field is cancer epidemiology. Based on case-control
studies association between exposure to risk factors and disease can be
investigated. This technique applies directly to human beings, which is
a major advantage. The impact of environmental factors or lifestyle (as
for example smoking) can be assessed based on observations of human
populations. No species barrier has to be overcome. But case-control
studies are very susceptible to bias and must be carried out carefully.
One of the first such work was Doll and Hill (1950), who associated
cigarette smoking to lung cancer. An extensive discussion of the use
of case-control studies in cancer research give Breslow and Day (1980).
Note that long term surveys become only now available; Doll et al.
(2004) for example give the first long term study (50 years) of mortal-
ity in relation to smoking. A related field is disease mapping, where
cancer incidence is examined for population subgroups and different
geographic regions.
Once a risk factor is identified, the dose-response relationship of the
corresponding agent is of main interest. Regulatory agencies wish to
define threshold values such that exposure to lower concentrations of
the given carcinogen is considered safe. In this process, very common
issues are the extrapolation from high doses to low doses, from labora-
tory animals to humans, and between different routes and patterns of
exposure. A very recent account of the state of the art in cancer and
human health risk assessment is given in Edler and Kitsos (2005).
Fundamental to the above topic is the understanding of the can-
cer causing mechanisms. Quantitative descriptions of the process that
transforms normal cells into cancer cells are provided by (stochastic)
carcinogenesis models. Generally, those models are linked stochastic
processes counting numbers of cells of different types present at a given
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time. The level of biological detail to be modelled determines the type
of theory to be used, for example Markov chains and branching pro-
cesses. If a carcinogenesis model is mechanistic, i.e. if it is the formal-
ization of the biological theory of cancer, then the model can be used to
test biological hypothesis about the process. Consequences of quantita-
tive models can thereby lead to insights into the biological mechanisms
for tumor onset. An excellent review of stochastic carcinogenesis mod-
els is given by Kopp-Schneider (1997).
Another important topic is the modeling of cancer growth and
evolution. Probabilistic models based on interacting-particle systems
(contact processes) and random sets have been proposed (see Cressie
(1991)). The aim is usually to derive asymptotic properties like con-
vergence to some shape or conditions leading to extinction. Another
very active research field is deterministic modeling of cancer growth,
where differential methods and numerical simulation are used. Very
often, this type of research is performed in close collaboration with
clinicians. The better understanding of cancer growth should help to
improve current treatments and can propose new strategies for therapy.
See Preziosi (2003) for the state of current research in this field.
Finally, we should mention the very active fields of microarray data
analysis, data mining and machine learning. The recent revolutions in
molecular biology and biotechnology have had a great impact on cancer
research. Many laboratories investigate patterns in gene expression of
cancer tissues. Expression patterns are clustered into groups, and new
cancer causing genes are identified. The enormous amount of data
collected gives rise to exciting opportunities in statistical research.
1.3 Short Review of Statistical Tools
In this section, we briefly introduce some selected statistical concepts.
The aim is to define the main methods that we will use later on. The
topics chosen are general issues in statistics and are not restricted to
cancer modeling. The reader with a solid statistical background will
already be familiar with them.
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1.3.1 Survival Analysis
Stochastic carcinogenesis models describe the waiting-time for tumor
onset. The main object of study is the random time T we wait (in our
case in years from birth) until some event of interest (in our case cancer)
occurs. The statistical field that studies such problems is called survival
analysis (other frequently used names are failure time data analysis,
lifetime data analysis, or time to event data analysis). Examples of
events considered might be infection with a disease in epidemiology,
breakdown of a machine in industry, or the beginning of a new work
contract for a person on unemployment as studied in the social sciences.
Clearly, the notion of time is central in survival analysis and deserves
special attention. Time origin and scale of a study must be selected
carefully. Continuous or discrete models for time can be appropriate,
and one is not restricted to physical or chronological time. For example
in biology a sensible time scale might be the number of divisions a
certain cell has undergone; or in engineering the number of items a
machine has produced might be a more interesting measure of age than
its actual lifetime in months or years. Objectives of survival analysis
are to understand how a disease functions, to identify covariates that
significantly affect failure times, to study if and how treatments increase
life expectancy etc.
We will now introduce very briefly the basic notions that will be
used extensively throughout this text. For a detailed discussion of
survival analysis see one of the many excellent textbooks that exist on
this subject as for example Kalbfleisch and Prentice (2002) and Lawless
(2003).
Continuous Failure Times
Let us first consider the case where the random variable T is continuous
with cumulative distribution function F (t) and density f(t) . In order
to characterize the distribution of T , we will use instead of F rather
the survivor function,
S(t) = P(T > t) = 1− F (t) ,
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or the hazard function (also called hazard rate, failure rate, or force of
mortality)
h(t) = lim
∆t↓0
1
∆t
P(t ≤ T < t+∆t |T ≥ t)
=
f(t)
S(t)
= − d
dt
log(S(t)) .
Let H(t) =
∫ t
0
h(u) du be the cumulative hazard. Then we have the
relation
S(t) = e−H(t) ,
which shows that the hazard function characterizes uniquely the dis-
tribution of T . Still another way to give the law of a survival time
variable is the expected residual life at t , defined as
r(t) = E(T − t |T ≥ t) ,
which is less general in the sense that it is defined only if T has a
finite mean. But if this is the case, r(t) specifies a unique probability
distribution.
The hazard function can be interpreted as instantaneous rate of
failure at time t, given the individual is still alive at time t . This
concept has been extremely successful in survival analysis and h(t) is
used extensively. Nonetheless, h(t) is a complicated function and its
interpretation is more difficult than one might expect at first sight. For
example when a population is observed, the monotonicity properties of
the overall hazard can be drastically different from the monotonicity
properties of the hazard functions of the single individuals due to a
frailty effect. Strictly increasing hazard functions can give rise to a
strictly decreasing population hazard under mixing. We will consider
this phenomenon more closely in Chapter 3.
Another point that needs some care is the interpretation of the
failure rate in terms of probabilities. Neither h(t) nor
∫ b
a
h(u)du is a
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probability, but h(t) dt is. However, as long as the cumulative hazard
is small enough,
H(t) ≈ 1− e−H(t) = 1− S(t) .
This means H(t) is a good approximation of the probability to fail in
the interval [0, t] for rare events or short time periods.
Discrete Failure Times
Analogous definitions can be given if T is a discrete random variable.
Let a1 < a2 < . . . be the (nonnegative) time-points with positive prob-
ability mass, and let us note
f(ai) = fi = P(T = ai) , i = 1, 2, . . . .
Then, the survivor function is given by the step function
S(t) =
∑
i|ai>t
fi .
In the discrete case, the hazard function at time ai is a probability,
namely the probability of failure at ai given survival up to ai ,
hi = P(T = ai |T ≥ ai) = f(ai)
S(ai−) .
Consequently, 1− hi is the probability not to fail at ai , given survival
up to this point. The survivor function can therefore be reconstructed
from the hazard in form of a product,
S(t) =
∏
i|ai≤t
(1− hi) .
In other words, the survivor function may be seen as arising from a
sequence of coin flipping experiments, such that at ai an item fails
with probability hi and moves on to the next point with probability
1−hi . The cumulative hazard can now be defined in two ways. Either
we set
H(t) =
∑
i|ai≤t
hi ,
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or we define
H∗(t) = −
∑
i|ai≤t
log(1− hi) ,
which has the advantage to keep the relationship S(t) = exp(−H∗(t)) .
Note that as long as hi is small, we have log(1− hi) ≈ −hi and thus
H(t) ≈ H∗(t) .
In this work, we will take the former definition for the cumulative haz-
ard in models with discrete time.
Besides purely continuous and purely discrete survival times, we
can also imagine mixed situations, where T has a continuous and a
discrete part. In this case, the cumulative hazard is given by a linear
combination,
H(t) =
∫ t
0
hc(u) du+
∑
aj≤t
hdj ,
and the survivor function can be decomposed in an analogous manner
as the product of a continuous and a discrete part.
Discretization of a Continuous Model
Later on in this thesis, we will apply continuous multistage carcinogene-
sis models to human cancer incidence data. Such data come commonly
in the form of counts of cases as a function of age, where ages are
binned into groups. That is we do not observe the actual failure time
of an item, but we know only during which interval of a given partition
{[ai−1, ai), i = 1, . . . , k} the event occurs. If we want to fit a continu-
ous model with survivor function S(t) and hazard function h(t) to such
data, we must transform it into the corresponding versions in discrete
time. For example the discretized hazard at ai is
λi =
S(ai)− S(ai+1)
S(ai)
.
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So the hazard rate per year at ai is
λi
ai+1 − ai =
1
ai+1 − ai
(
1− e−[H(ai+1)−H(ai)]
)
≈ H(ai+1)−H(ai)
ai+1 − ai
≈ h(ai) ,
where the approximations hold if H(ai+1) − H(ai) and ai+1 − ai are
small enough. Note that λi is bounded by one since it is a condi-
tional probability. Therefore, also the discretized hazard rate per year
is bounded, while the hazard function of the continuous model , h(t) ,
is not. This effect can cause considerable bias. Figure 2 below shows
the effect of discretization of a Weibull model as the time axes is split
into five year intervals.
For rare events like cancer, where the incidence rates are extremely
low, we can directly compare continuous hazard curves to discretized
data. If, however, the above approximations are poor, then we must
transform the model into its discretized version in order to compare
models to data.
Censoring and Estimation
As described above, we will work mainly with grouped data. This is
a special form of censoring. In general, censoring means that we do
not observe the actual failure time, but only some derived informa-
tion. In order to illustrate this, let there be given n individuals with
lifetimes T1, . . . , Tn . In the case of grouped data, we do not observe
the Tj . Instead we only know into which interval from a given parti-
tion {[ai−1, ai) , i = 1, . . . , k} these times fall. A more general scheme
would be to replace the fixed intervals by random ones. In this case,
we observe instead of Tj a pair of random variables (Lj , Uj) , such that
Tj ∈ [Lj , Uj ] . Another very common situation is right-censoring, which
means that for some individuals we only know that their survival time
Tj exceeds a possibly random censoring time Cj . Instead of Tj , we
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Figure 2: Survivor and hazard function of the Weibull model with shape
parameter n = 4 and scale parameter θ = 50 . The red curve gives the hazard
rates per year λi/(ai+1 − ai) , where ai = 5 · i , i = 0, 1, . . . .
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observe (min{Tj , Cj}, I{Tj≤Cj}) , where IA is the indicator function of
event A. Many other censoring-mechanisms are possible and form the
core of a lot of issues in survival analysis.
Finally, let us introduce two very useful classical non-parametric
estimators - one of the cumulative hazard, and one of the survivor
function respectively. For this purpose, let there be given a sample of
right censored survival times, (ti, δi) , i = 1, . . . , n , where δi = 1 if ti
is an observed failure time and δi = 0 if ti is a censoring time. So
k˜ =
∑n
i=1 δi elements out of the list t1, . . . , tn are effectively observed
failures. We will denote the time points at which these failures occurred
by a1 < a2 < · · · < ak . Note that k ≤ k˜ , and k < k˜ if there are ties.
Suppose that di items fail at ai and mi are censored during the interval
[ai, ai+1) . Let ni =
∑k
j=i(dj + mj) be the population at risk at ai .
A natural way to estimate the discrete hazard at ai is to take the
empirical hazard, that is, the observed failures among the population
at risk. Formally,
λˆi =
di
ni
,
which leads to the Nelson-Aalen estimator for the cumulative hazard,
Λˆ(t) =
∑
ai≤t
di
ni
.
The function Λˆ(t) characterizes a discrete distribution, which has the
survivor function
Sˆ(t) =
∏
ai≤t
(1− λˆi) .
This estimate Sˆ(t) is well known in survival analysis. It is the so-called
Kaplan-Meier or product limit estimate of the survivor function.
In order to get variance estimates of Λˆ(t) and Sˆ(t) , one exploits
the fact that the empirical hazards can be derived using maximum
likelihood theory. In fact, it can be shown that the λˆi, i = 1, . . . , k , are
asymptotically independent with variances estimated by λˆi(1− λˆi)/ni .
This leads to an estimate of the asymptotic variance of the Nelson-
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Aalen estimator,
V̂ar(Λˆ(t)) =
∑
ai≤t
di(ni − di)
n3i
.
The above result in combination with the delta method gives an esti-
mation of the variance of the Kaplan-Meier estimator,
V̂ar(Sˆ(t)) = Sˆ(t)2
∑
ai≤t
di
ni(ni − di) ,
called Greenwood’s formula.
In the case of grouped data, we may want to slightly modify the
above expressions. Let I1, . . . , Ik denote the intervals Ii = [ai, ai+1) .
We can now interpret di, mi , and ni as the number of failures during
Ii , the number of censorings during Ii , and the number of individuals
at risk at the beginning of Ii . The empirical hazard as introduced
before, λˆi = di/ni, does not account for the fact that also some of the
censored individuals may fail before ai+1 . Or, in other words, not all
the ni individuals are at risk for the whole interval Ii . A commonly
used adjustment replaces λˆi by
λˆ′i =
di
ni −mi/2 ,
and we get the so-called life-table estimator for the survivor function,
SˆLT(ai) =
i∏
j=1
(1− λˆ′j) .
We obtain a similar expression for the variance of SˆLT(ai) as before by
substituting ni with n′i = ni −mi/2 in Greenwood’s formula.
1.3.2 Counting Processes
We will now briefly introduce the counting process framework of lifetime
models. This formalism is widely used in survival analysis and provides
a large supply of concepts and results from probability theory. The
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use of counting process notations for statistical analysis of failure time
data has been introduced by Aalen (1975). A thorough discussion of
the subject give Andersen et al. (1993).
A counting process {N(t), t ≥ 0} is a stochastic process such that
N(0) = 0 and N(t) counts the number of events that have occurred in
the interval (0, t] . In the case of a survival study, it is very natural to
consider processes that count the number of individuals that have failed
up to time t . Let us suppose that the survival times are right censored,
that is we observe a sequence of pairs (min{Ti, Xi}, I{Ti≤Xi}) , i =
1, . . . , n . We can now define the underlying counting process
N˜i(t) = I{Ti≤t} ,
which counts the events that have occurred during the interval (0, t] for
individual i . Similarly, the process of observed failures is
Ni(t) = I{Ti≤t, Ti≤Xi} ,
and the at risk process is
Yi(t) = I{Ti≥t, Xi≥t} .
We can now express the process of observed failures in terms of N˜i(t)
and Yi(t) ,
Ni(t) =
∫ t
0
Yi(u) dN˜i(u) .
The total number of observed failures is N(t) =
∑n
i=1Ni(t) , and the
population at risk is Y(t) =
∑n
i=1 Yi(t) .
Throughout this text, we will consider independent censoring, that
is Ti and Xi are independent. We will focus on the special case, where
Xi are i.i.d. with an unknown distribution function G , and also Ti are
supposed to be i.i.d. Their distribution is specified by the cumulative
intensity function Λ(t) , which can now be characterized by
dΛ(t) = P( dN˜i(t) = 1 | N˜i(t−) = 0) .
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In order to link Λ(t) to the observed events process Ni(t) , we must
specify the history,
Ft = σ{Ni(u), Yi(u+), i = 1, . . . , n ; 0 ≤ u ≤ t} .
With this definition the at-risk processes Yi(t) are predictable with
respect to the filtration Ft . This means that if we know everything
that happened up to time t−, then we also know which individuals
are at risk at t and which are not. The assumption of independent
censoring leads to the multiplicative intensity model,
P( dNi(t) = 1 | Ft−) = Yi(t) dΛ(t) .
In our case, Λ(t) is a deterministic function, and therefore Yi(t)dΛ(t) is
predictable. The power of the counting process framework for deriving
asymptotic properties comes from the fact that
Mi(t) = Ni(t)−
∫ t
0
Yi(u) dΛ(u)
is a zero mean martingale. In other words, Ni(t) splits into two parts:
a systematic part,
∫ t
0
Yi(u) dΛ(u) , called the counting process compen-
sator, and a purely random part, Mi(t) , which is called the counting
process martingale. The martingale Mi(t) is called square integrable
if E(M2i (t)) < ∞ for all t. If Mi(t) is square integrable, then its pre-
dictable variation process is defined as
〈Mi〉(t) =
∫ t
0
Var( dMi(u) | Fu−) .
It can be shown, that 〈Mi〉(t) is the compensator of M2i (t) , which
implies that M2i (t)−〈Mi〉(t) is a mean zero martingale. It follows that
Var(Mi(t)) = E
(〈Mi〉(t)) .
In other terms, 〈Mi〉(t) is an unbiased estimator of the variance of
Mi(t) . Similarly, for two individuals we get martingales Mi(t), Mj(t) ,
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which are defined on the same filtration. Their predictable covariation
process is defined as
〈Mi,Mj〉(t) =
∫ t
0
Cov( dMi(u), dMj(u) | Fu−) ,
and Mi(t), Mj(t) are said to be orthogonal if 〈Mi,Mj〉(t) = 0 for all
t . Based in Mi(t) , we can construct new martingales in quite general
ways. Let G(t) be a bounded predictable process, then also
U(t) =
∫ t
0
G(u)dMi(u)
is a mean zero martingale. If Mi(t) is square integrable, then also U(t)
will be so, and we have
〈U〉(t) =
∫ t
0
G2(u) d〈Mi〉(u) .
The estimators introduced in Section 1.3.1 can be expressed in such a
form. Let J(t) = I{Y(t)>0} and let us take the convention 0/0 = 0 .
Then, for example the Nelson-Aalen estimator becomes
Λˆ(t) =
∫ t
0
J(u)
Y(u)
dN(u) .
Asymptotic properties of such estimators can now be derived using mar-
tingale central limit theory. In particular, let us mention the following
version of Rebolledo’s theorem. Let U (n)(t) = (U (n)1 (t), . . . , U
(n)
g (t)) be
a vector-valued martingale, where n denotes the size of the population.
Suppose that U (n)i (t) can be written in the form
U
(n)
i (t) =
∫ t
0
G
(n)
i (u) dM
(n)(u) ,
where G(n)i (t) is a predictable process. We must introduce for given
 > 0 the process
U
(n)
i (t) =
∫ t
0
G
(n)
i (u)I{|G(n)i (u)|>} dM
(n)(u) .
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Let there exist a positive semi-definite g × g-matrix V (t) such that
V (0) = 0 , V (t) − V (s) is positive semi-definite for all 0 ≤ s ≤ t , and
V (t) right continuous. Then, from
〈U (n)〉(t) P−→ V (t) as n→∞ , and
〈U (n)i 〉(t) P−→ 0 as n→∞ for all i and  > 0 ,
it follows that
U (n)(t) D−→ N (0, V (t)) as n→∞ .
1.3.3 Mixture Models
One objective of this work is to study multistage carcinogenesis models
in relation to heterogeneity. It is well known that susceptibility to
cancer varies among individuals due to both genetic and environmental
factors. Mixture models will present a way to account for such hidden
differences.
Let us consider a continuous failure time T with survivor function
S(t|θ) depending on some parameter θ . If the observed population is
not homogeneous with respect to θ , we may suppose that there exists
a distribution function G(θ) , which quantifies the variation of θ . The
observed population survivor function is
S(t) =
∫
S(t|θ) dG(θ) .
A similar expression can be derived for the hazard function of such a
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model,
h(t) = lim
∆t↓0
1
∆t
P(t ≤ T < t+∆t |T ≥ t)
= lim
∆t↓0
1
∆tS(t)
∫
P(t ≤ T < t+∆t | θ) dG(θ)
(∗)
=
1
S(t)
∫
f(t|θ) dG(θ)
=
∫
h(t|θ)S(t|θ)
S(t)
dG(θ) ,
where (∗) holds if the limit operation and the integration can be inter-
changed. In the sequel, we will call S(t) a mixture model with mixing
distribution G(θ) and components S(t|θ) .
An important point in building sound models is identifiability. Let
G be a given set of candidate distributions for G . Then, G induces a
set of mixture models,
S =
{∫
S(t|θ) dG(θ) ; G ∈ G
}
.
The family of mixture models S is said to be identifiable (with respect
to G), if the implication∫
S(t|θ) dG1(θ) ≡t
∫
S(t|θ) dG2(θ) =⇒ G1 ≡θ G2
holds for all G1, G2 ∈ G . In other words, the population survivor
function must determine uniquely the underlying mixing distribution
within a pre-specified family. This condition turns out to be hard to
verify in general settings, and useful results exist only for special cases.
1.3.4 Analytic Graduation
All the statistical tools we have described up to now aim at the speci-
fication of models for survival data. As a last topic in this short review
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of some methodology we will focus on an issue related to parameter
estimation. In Chapter 5 we will fit stochastic carcinogenesis models
to grouped cancer incidence data. That means we want to estimate
a parameter θ from data of the form (ri, oi) , i = 1, . . . , N , where ri
counts the population at risk at ti , and oi counts the observed cases
during time interval [ti, ti+1) . The basic idea of analytic graduation is
to derive raw hazard estimates, λˆi , and then to fit the parametric haz-
ard h(t; θ) evaluated at some representative time points. For example,
one can take the occurence/exposure rates as raw estimates,
λˆi =
oi
ri(ti+1 − ti) ,
and the midpoints t∗i = (ti + ti+1)/2 , where we suppose that tN+1 is
finite. Let λˆ = (λˆ1, . . . , λˆN )T and h(t∗; θ) = (h(t∗1; θ), . . . , h(t∗N ; θ))
T .
Using this notation, we obtain an estimate θˆ by minimizing the quadratic
form
Q(θ) = (λˆ− h(t∗; θ))TM(λˆ− h(t∗; θ)) ,
where M is a positive definite symmetric matrix. So for example if M
is the identity matrix, then θˆ is the least squares estimate. In order to
get asymptotic properties of θˆ , we need regularity conditions. Namely,
we make the assumptions
1) θ varies in an open subset Θ of Rp ;
2) J(θ) , where (J(θ))ij = ∂∂θj h(t
∗
i ; θ) , is of full rank for all θ ∈ Θ ;
3) as a function of θ , h(t; θ) is one-to-one, bicontinuous, and contin-
uously differentiable;
4) if n is the total number of items in the study, then
√
n(λˆ− λ0) D−→ N (0,Σ0)
as n→∞ for a vector λ0 and a positive definite matrix Σ0 .
Let θ0 denote the true value of θ , then under 1) - 4) we have that
√
n(θˆ − θ0) D−→ N (0,Σ) ,
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where
Σ = (JT0 MJ0)
−1JT0 MΣ0MJ0(J
T
0 MJ0)
−1
and J0 = J(θ0) .
The method of analytic graduation is important in demography for
the analysis of vital rates. The main motivation for its development
was that raw hazard estimates, extracted for example from mortality
tables, gave rise to rather rough curves when plotted against age. How-
ever, there was supposed to be an underlying smooth mortality curve.
Graduation was used to fit such smooth models to the wiggling raw
hazard estimates. A detailed discussion can be found in Hoem (1972,
1976).
1.4 Outline
We finish this introduction with a short outline of the remainder of this
work. In Chapter 2, we first review the general stochastic multistage
carcinogenesis model. Then, we explain the special case that will be
used extensively in all subsequent parts of this text. The chapter is
very short, since we take up an existing and well known carcinogenesis
model.
The aim of this thesis is to introduce the concept of population
heterogeneity into the multistage carcinogenesis model. We achieve this
by the means of mixture modeling, and our extension to the multistage
model is given in Chapter 3.
Chapter 4 treats identifiability of both the multistage model itself
and the mixture structure we introduce. We extend known results
from the two-stage case to the multistage version of the model. Next,
we prove the identifiability of our mixture model.
In Chapter 5, we present applications of the mixture model to hu-
man cancer incidence data. In particular, we discuss problems encoun-
tered with maximum likelihood estimation and apply analytic gradua-
tion, which was described in the previous section, to our case.
Finally, in Chapter 6 we consider population heterogeneity itself
and discuss related statistical issues. By doing so, we end this thesis
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with a presentation of some of the present challenges for the application
of statistical methods in cancer research.

CHAPTER 2
Stochastic Carcinogenesis Models
2.1 Historical Review
The development of mathematical carcinogenesis models began around
the 1950s. It was related to the insight that mutations could eventually
cause cancer. The corresponding biomedical theory that established the
possibility of a mutational origin of tumors can be traced back to the
first half of the 20th century and is associated with names such as Karl
Heinrich Bauer and Theodor Boveri. See Edler and Kopp-Schneider
(2005) for a short review.
One of the first attempts to build a biologically based quantita-
tive description of the process leading to cancer was Nordling (1953),
who investigated cancer mortality as a function of age. Using data from
several countries, he observed a linear dependency on a log-log scale be-
tween mortality λ and age t . He concluded, that λ(t) ∝ tn−1 , where n
is the number of mutations needed to cause cancer. The data suggested
seven mutational events. Armitage and Doll (1954) further developed
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this idea. They assumed that successive discrete events are required
for tumor development, where the cellular changes involved must not
necessarily be mutations. They also studied time varying carcinogenic
factors. However, such multi-hit models did not account for the growth
dynamics of pre-neoplastic cells. A first two stage theory was proposed
by Armitage and Doll (1957) , who used exponential growth of inter-
mediate cells. Kendall (1960) introduced the theory of stochastic pro-
cesses into carcinogenesis modeling, taking birth-and-death processes
to describe cell proliferation.
These early works form the bases of the mathematical multistage
theory of carcinogenesis and led finally to the classical two stage model
in Moolgavkar and Venzon (1979); Moolgavkar and Knudson (1981).
Their two-stage clonal expansion (TSCE) model stipulates that normal
dividing cells degenerate to cancer cells via two stages: an initiating
stage, where a mutation leads to some growth advantage, and a sub-
sequent promotion stage, in which the population of initiated cells ex-
pands and thereby increases the number of target cells that might turn
into a tumor. The approach stressed the importance of both mutations
and clonal expansion in the process leading to cancer. This model is
probably the most widely accepted mechanistic model of carcinogen-
esis. In the literature it is often called Moolgavkar-Venzon-Knudson
(MVK) two-stage model instead of TSCE model.
The TSCE model has found many applications. Let us mention
some of the extensions that have been introduced: Moolgavkar and
Luebeck (1990) discuss time dependent parameters, Kopp-Schneider
and Portier (1994) incorporate stem cells into the model, Little (1995)
investigates the number of mutations needed to cause cancer, and Little
and Wright (2003) take genomic instability into account. General mul-
tistage models, as the one shown in Figure 3, take up the same structure
as the TSCE model, but allow for more than one intermediate stage.
As we will see later on, the TSCE model leads to rather cumbersome
expressions, and an exact formula of the survivor function that did not
require numerical integration was derived only in Kopp-Schneider et al.
(1994) and in Zheng (1994). Another important issue is identifiability,
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Figure 3: A general multistage model: normal cells at risk, N , are trans-
formed via n+1 discrete events into tumor cells, T . The events are supposed
to be irreversible, and the normal and intermediate cells divide and die or dif-
ferentiate. Division is either symmetric and leads to two identical daughter
cells, or it is asymmetric and leads to a normal daughter cell and a daugh-
ter cell entering the next compartment. Growth of the tumor cells is not
considered.
which will be discussed extensively in Chapter 4.
Due to this long history, we should not have in mind a single model
when talking about the multistage model. We should rather think
of a cascade of nested models that starts from a fundamental idea
and incorporates through its evolution more and more biological detail.
Excellent reviews of stochastic carcinogenesis modeling can be found
in Whittemore and Keller (1978), Tan (1991), Kopp-Schneider (1997)
and Edler and Kitsos (2005).
2.2 The Multi-Hit Model
The multi-hit model of carcinogenesis assumes that a normal cell is
transformed into a cancer cell via a sequence of n discrete events, or
hits, as shown in Figure 4.
The model does not account for cell dynamics such as cell division and
differentiation. The structure given in Figure 4 is the one proposed in
the articles of the early 1950s. Armitage and Doll (1954)1 show that
1Note that in their article, Armitage and Doll talk of a multi-stage theory of
carcinogenesis. Nevertheless, we will use the term multi-stage only in connection
with clonal expansion models as the one given in the next section.
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Figure 4: A normal cell is transformed into a cancer cell via discrete events
that occur at rates ν1, . . . , νn .
the hazard rate for the transformation of a single cell via n steps is
approximately
h(t) =
ν1 . . . νn
(n− 1)! t
n−1 (1)
if the hits must occur in a given order. If we assume that the events
can happen in any order, we must multiply the above expression by
n! . This process is equally likely to take place in any of the cells at
risk. If we suppose the number of cells at risk, N0 , to be constant over
time, then the overall incidence rate for an organism is N0 times the
incidence rate for a single cell.
Note that Armitage and Doll used an approximation to derive (1).
Let us consider a single hit that can occur at any moment. Then,
the time to event is exponentially distributed, X ∼ E(ν) , and the
probability of the event to happen in the interval (0, t) is
P(X ∈ (0, t)) = 1− e−νt = νt+ o(νt) .
The hazard function of the multi-hit model with n hits is derived in
the following way. The first n − 1 hits occur in (0, t) . So under in-
dependence and for equal rates the corresponding probability is ap-
proximately (νt)n−1 . If we impose a given order, we must divide this
probability by (n − 1)! . The last event happens in the short interval
(t, t+ dt) , with probability ν dt . Putting these parts together, we get
the probability of the nth transformation to happen at time t , namely
h(t) dt , where h(t) is as given in (1).
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This approximation is valid as long as νt is small. Moolgavkar
(2004) and Moolgavkar and Luebeck (2003) state that this simplified
model can be applied if the probability of getting cancer is low - as
usually is the case in human population data. But the approximation is
poor in other settings like experiment data with high tumor probability.
In any case, the theoretical properties as for example the asymptotic
behaviour change with respect to the exact solution.
From now on, we will call multi-hit model the version given by the
hazard function
hMH(t) = nνnN0tn−1 .
That is, we only consider the case with equal rates ν1 = · · · = νn = ν
for the n hits. The corresponding survivor function is
SMH(t) = e−ν
nN0t
n
.
In other words, the waiting time for tumor onset is modelled as a
Weibull with shape parameter n and scale parameter (ν n
√
N0)−1 .
2.3 The Multistage Carcinogenesis Model
The structure of a general multistage model has been given in Figure 3.
The classical approach to derive the survivor function of such a model
uses the probability generating function,
ϕ(s; t) =
∑
i0,...,in+1
si00 · . . . · sin+1n+1 · P(N(t) = i0, . . . , T (t) = in+1) ,
of the vector
(N(t), I1(t), . . . , In(t), T (t)) ,
which counts the number of cells in the different compartments. Kol-
mogorov’s equations yield differential equations for ϕ(s; t) , which may
eventually be solved along characteristics.
Throughout this text, we will work with a simplified version of the
multistage model, but a version that is general enough to incorporate
all the main features of the carcinogenesis process. The model is shown
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schematically in Figure 5. Note that we get the classical TSCE model
if n = 1 . We see also that the step called initiation in this multistage
model corresponds precisely to the multi-hit model, but as an extension
the multistage model incorporates also promotion.
N0 I1 I2 . . . In T-
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Figure 5: N0 denotes the number of normal cells. To get initiated, a normal
cell accumulates n consecutive mutations, where ν denotes the mutation rate
per cell per year for the gene in question. The number of cells having accu-
mulated k mutations is noted Ik, 1 ≤ k ≤ n . The fully initiated cells, In ,
divide into two identical daughter cells and differentiate or die. Eventually,
a cell out of a clone of initiated cells may divide asymmetrically and give rise
to a tumor cell T . Note that µ/(µ+ β) can be interpreted as the probability
that a promoted cell is created during a cell division.
The same structure has been used by Luebeck and Moolgavkar
(2002), who derived the exact survivor and hazard functions for the
cases n = 1, 2, 3, 4 . In our work, we will use an approximation of the
Armitage-Doll type for initiation. This means we use the same model
as Morgenthaler et al. (2004), who give a detailed discussion and deriva-
tion for this case. More precisely, we make the following assumptions:
1) a cell must undergo n mutational events to get initiated;
2) the number of cells at risk, N0 , is constant over time;
3) the number of initiated cells is a non-homogeneous Poisson pro-
cess with intensity λI(t) ;
4) an initiated cell gives rise to a clonal expansion according to a
birth-and-death process with emigration (promotion), i.e. in a
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short time interval (t, t+∆t) an initiated cell divides in two ini-
tiated cells with rate β , dies or differentiates with rate δ(< β) ,
and divides into one initiated and one malignant cell with rate µ ;
5) once a promoted cell is generated, its growth is deterministic, and
we neglect the time needed to grow to detectable tumor size;
6) the system starts with all susceptible cells in the normal state
and the different cells act independently of one another.
Under the above conditions, the survivor function for tumor onset
can be represented as
S(t) = exp
{
−
∫ t
0
λI(x)FP (t− x) dx
}
, (2)
where the intensity of initiation is
λI(x) = nνnN0xn−1 , (3)
and FP (x) is the cdf for the waiting time for the first malignant trans-
formation within a clone starting with one initiated cell at time 0. This
function is improper since a clone of initiated cells may die out with a
probability greater than 0. Its exact form is
FP (x) =
(β − δ − µ+∆)(β − δ − µ−∆)(e−∆x − 1)
2β[(β − δ − µ+∆)e−∆x − (β − δ − µ−∆)] , (4)
where ∆ =
√
(β + δ + µ)2 − 4βδ . The hazard function can be easily
calculated from the survivor function, and we get
h(t) =
∫ t
0
λI(x)F ′P (t− x)dx ,
where (·)′ = ddt (·) . In order to deduce the asymptotic behaviour of the
hazard for several n , the following representation is useful. First note
that ∫ t
0
λI(x)FP (t− x) dx =
∫ t
0
λI(t− x)FP (x) dx .
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So we can calculate the hazard also as
h(t) =
d
dt
∫ t
0
λI(t− x)FP (x) dx .
This implies that
h(t;n) =
νN0FP (t) , if n = 1 ;−nν log(S(t;n− 1)) , if n ≥ 2 ;
or in terms of a recursion,
h(t;n) =
νN0FP (t) , if n = 1 ;nν ∫ t
0
h(u;n− 1) du , if n ≥ 2 .
This shows that for n = 1 the hazard levels off as t goes to infinity. More
precisely, the hazard of the TSCE model goes to the finite asymptote
νN0 · P(a clone of initiated cells survives) .
But the hazard grows to infinity if n ≥ 2 . In any case, h(t;n) is strictly
monotonic increasing with t .
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CHAPTER 3
Mixtures of Multistage Models
3.1 Heterogeneity
In Chapter 2 we presented models that describe carcinogenesis at a cel-
lular level. We then assumed independent and identical behavior of all
the cells at risk of an organism to get a model for a single individual.
If we apply this model directly to human cancer incidence data, then
the same model is used for the whole population. However, the risk
of developing cancer is not equal for everyone. One can easily think
of many biological mechanisms and environmental settings that would
induce heterogeneity. For example germ line mutations in oncogenes or
tumor suppressor genes produce inheritable factors. This leads to new-
borns that start life with all cells in some intermediate stage. But also
a genetically based overall predisposition to cancer for some individuals
is plausible. Moreover, exposure to carcinogens varies due to changes
in environment and occupation. Therefore, incidence rates are specific
for different population subgroups. Such considerations are common is-
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sues in survival analysis. For example Vaupel and Yashin (1985) give a
very nice introduction into the effects of unobserved heterogeneity, and
Aalen (1994) and Hougaard (1995) review frailty modeling in survival
analysis.
In our work, we aim at introducing population heterogeneity into
the multistage carcinogenesis model presented in Section 2.3. First of
all, let us have a brief look at the approaches that have been proposed
up to now. Some work has been done by Tan (1988), who developed a
general mixed model of one-stage and two-stage models, and Tan and
Singh (1990), who applied the special case of a one-stage and a two-
stage model to data from retinoblastoma, a cancer of the eye affecting
most often small children. Their model is particularly well suited for
the description of cancers with early onset for a part of the population,
since the one-stage component will cause a peak in the overall hazard at
young ages. Biological theory strongly supports their mixture model.
Retinoblastoma (RB) is caused by mutations in both copies of a gene
called RB1, and thus heterozygous individuals have a hereditary pre-
disposition. Additionally, RB does occur in both forms, hereditary and
non-hereditary.
Aalen and Tretli (1999) and Moger et al. (2004) use standard frailty
modeling to analyze testicular cancer incidence data from Scandinavian
registries. More precisely, they model the hazard function for an indi-
vidual as the product of a non-negative frailty Z and a baseline hazard
function, hind(t|Z) = Z ·h0(t) . They chose the multi-hit hazard as base-
line h0(t) and model Z by the compound Poisson distribution. This
frailty distribution allows for two main underlying states for an individ-
ual: either Z = 0 , that is the individual is not susceptible, or Z > 0 ,
which means the individual is susceptible and its relative risk with re-
spect to the baseline is distributed as the sum of independent gamma
variables. Both states occur with strictly positive probability and the
proportion of non-susceptibles, P(Z = 0) , is a parameter of main in-
terest. A more basic version of the same model investigate Izumi and
Ohtaki (2004). These authors assume Z be gamma distributed. In
other words, they take the Weibull-gamma frailty model and apply it
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to data from Japanese atomic bomb survivors.
A different approach is proposed by Morgenthaler et al. (2004), who
introduce two new population parameters to describe variability among
individuals. The first one, called fraction at risk, quantifies the propor-
tion of susceptibles. The second one, called fraction of deaths due to
the cancer among all deaths due to either cancer or related causes,
describes the behaviour of competing but related risks. These authors
combine the two parameters with the multistage model given in Section
2.3 and analyze lung cancer incidence data from US birth cohorts.
The multistage model is a mechanistic model, so all its parameters
have a natural biological interpretation. It is therefore desirable to
introduce also the notion of frailty in a biologically meaningful way
into the model. The extension by mixture presents such a possibility,
and we will take up this approach in our work. We can focus attention
on any of the parameters and not just on the number of mutations
that are necessary to induce a cancer. If we assume a parameter be
a random variable, then the population hazard arises as a mixture.
Before we study mixtures of carcinogenesis models, let us make some
general remarks on the hazard rates we will get.
3.2 Hazard Rates of Mixture Models
Recall Section 1.3.3, where we have seen that under suitable regularity
conditions, the hazard rate of a mixture model can be written as
h(t) =
∫
h(t|θ)S(t|θ)
S(t)
dG(θ) , (5)
where G(θ) is the mixing distribution function and h(t|θ) , S(t|θ) are
the component hazard and survivor functions. Two features of h(t) will
be of main interest for us: monotonicity, and the asymptotic behaviour.
Especially, it is important to know if and under which conditions the
properties of the components h(t|θ) are invariant under mixing and still
hold for h(t) . Regarding monotonicity, we must distinguish the two
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cases of distributions with an increasing failure rate (IFR), and distri-
butions with a decreasing failure rate (DFR). From reliability theory it
is known that the DFR property is preserved under mixture. However,
one can show that the mixture of IFR distributions can be DFR. See
Barlow and Proschan (1975), Lynch (1999)and Shaked and Spizzichino
(2001) for a detailed account. Gurland and Sethuraman (1995) extend
these results to the notion of ultimately IFR/DFR, meaning that the
monotonicity property holds for all t larger than some threshold value
t0 . In other words, it can be useful to consider separately the behaviour
of h(t) at high ages. General results on the asymptotic properties of
h(t) give Block et al. (2003).
In order to investigate the properties of h(t) , it is useful to distin-
guish cases. If the mixing distribution G(θ) is finite with probability
mass pii at θi , then equation (5) becomes
h(t) = pi1
S(t|θ1)
S(t)
h(t|θ1) + · · ·+ pinS(t|θn)
S(t)
h(t|θn) . (6)
That is the weight of component h(t|θi) is time dynamic and equals the
proportion of survivors of group i at time t among all survivors at time
t . Another useful representation is obtained exploiting the fact that
S(t) = pi1S(t|θ1) + · · ·+ pinS(t|θn) .
Introducing this expression into (6), we obtain
h(t) =
pi1S(t|θ1)h(t|θ1) + · · ·+ pinS(t|θn)h(t|θn)
pi1S(t|θ1) + · · ·+ pinS(t|θn)
=
pi1
S(t|θ1)
S(t|θn)h(t|θ1) + · · ·+ pin−1
S(t|θn−1)
S(t|θn) h(t|θn−1) + pinh(t|θn)
pi1
S(t|θ1)
S(t|θn) + · · ·+ pin−1
S(t|θn−1)
S(t|θn) + pin
.
If we have an ordering of the survivor functions such that
lim
t→∞
S(t|θi)
S(t|θn) = 0 , ∀ i < n , (7)
then this implies that asymptotically h(t) will behave like the hazard of
the strongest component of the mixture, h(t|θn) . Condition (7) means
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that the dying out of the nth group comes later than the dying out
of all other groups. We will see this condition again in relation with
identifiability in the next chapter.
In the continuous case, the population hazard
h(t) =
∫
h(t|θ)S(t|θ)
S(t)
g(θ)dθ
is often difficult to investigate unless strong restrictions are put on
h(t|θ) and g(θ) .
In conclusion, we must realize that the hazard rate is a difficult
concept, especially if we consider a heterogeneous population. Due to
a frailty effect, we can observe hazard rates with peaks, while all indi-
vidual hazards are strictly monotonic; or IFR distributions can become
DFR under mixing. This raises the question which underlying pro-
cesses can generate an observed population hazard curve and which
mechanisms would not be able to do so. An approach that is related
to this issue is presented in Aalen and Gjessing (2001), who consider
first passage time models for survival analysis.
3.3 Mixing the Multi-Hit Model
In a first step, we will consider the multi-hit model presented in Section
2.2. Recall the hazard and survivor function,
hMH(t) = nνnN0tn−1 ,
SMH(t) = e−ν
nN0t
n
,
where n counts the number of hits, ν is the rate at which such hits oc-
cur, and N0 is the number of susceptible cells. The multi-hit model has
the mathematically appealing Weibull form, and it is a natural simpli-
fication of the multistage model. Therefore, it is a useful structure for
a preliminary study of the extension of carcinogenesis models through
mixture. We will consider the multistage model in the next section.
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A Finite Mixture Model
Let us consider the number of mutations needed to cause a cancer. If
we assume different numbers of mutations for different population sub-
groups, then we get a finite mixture with population survivor function
S(t) =
k∑
i=1
piiSMH(t|ni) , (8)
where 1 ≤ n1 < n2 < · · · < nk are non-negative integers, 0 < pii < 1 ,
and pi1 + · · ·+ pik = 1 . Note that we have
SMH(t|ni + 1)
SMH(t|ni) = exp {−ν
niN0t
ni(νt− 1)} t→∞−−−−−→ 0 .
According to equations (6) and (7), this shows that the population haz-
ard h(t) approaches component hMH(t|n1) as t increases. In particular,
if n1 = 1 , then the population hazard h(t) levels off at the value νN0
as t→∞ . But if n1 > 1 , then h(t) is ultimately increasing to infinity.
Whether h(t) is strictly monotonic increasing for all t ∈ [0,∞) or has
peaks depends on the specific combination of components and weights
(ni, pii), i = 1, . . . , k . For many typical cases the population hazard
has peaks as the different population subgroups die out.
Figure 6 illustrates the survivor function and the hazard for a pop-
ulation with three groups. A very small one that needs only four mu-
tations to cancer leads to a peak at young ages. A second group, quite
small as well, of high risk individuals, which cause an increase in cases
from the age of about forty. And a last group that is at very low risk.
Groups two and three have a behavior close enough to cause h(t) to
be strictly monotonic from about the age of forty; the population haz-
ard has only one peak, which corresponds to the dying out of the first
group.
A Continuous Mixture Model
We can also consider continuous mixture models. Biologically, it would
be most natural to focus on the rate ν and to model this parameter with
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Figure 6: Population survivor function S(t) and population hazard function
h(t) for a multi-hit mixture model. The three components differ by the values
chosen for parameter n, namely n1 = 4 , n2 = 5 and n3 = 6 . The mixing
weights are pi1 = 0.01, pi2 = 0.045 and pi3 = 0.945 . The remaining parameters
are equal for all components with values ν = 7 · 10−5 , N0 = 1011 . The
dashed lines give the individual survivor functions SMH(t|n1) (red), SMH(t|n2)
(green) and SMH(t|n3) .
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some continuous distribution. Due to the special structure of the multi-
hit model, however, we will make some rather general observations here.
Let us write the survivor function of the multi-hit model in the
following form,
S˜MH(t) = e−θt
n
, (9)
where θ > 0 , and n > 1 is considered fixed. Then, S˜MH(t) is a particular
case of a survivor function of the form
S =
{
Sλ(t) = e−λG(t) , λ > 0
}
,
where G(t) is an increasing convex function such that G(0) = 0 and
G(t) ↑ ∞ as t ↑ ∞ . The set S is called an IFR Lehmann family based
on the cumulative hazard function G(t) . In other words, S consists
of all survivor functions that stem from a proportional hazards model
with baseline cumulative hazard G(t) , since the cumulative hazard cor-
responding to Sλ(t) is
Hλ(t) = λG(t) .
Gurland and Sethuraman (1995) study mixture models with kernel S
for several mixing distributions for λ. They are mainly interested in
cases such that the IFR property of G(t) is reversed, that is, where the
hazard of the mixture is either decreasing or ultimately decreasing. In
particular, these authors show that if we take the survivor function (9)
and model θ with a gamma distribution, then we get a model that is
ultimately DFR. Note that their result does not impose conditions on
the gamma distribution chosen.
The fact that the pooling of IFR Weibull variables can yield a DFR
variable crucially depends on the mixing distribution used. In the case
of the multi-hit model with (the aggregated) parameter θ , we cannot
take the gamma distribution if we wish to keep a biologically reasonable
setting. As a minimal requirement we must assume that the density
f(θ) has bounded support. Let us consider the case
supp{f} = [θl, θu] ⊂ R>0 .
For the hazard function
h˜MH(t|θ) = θntn−1 ,
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we have the natural ordering h˜MH(t|θ1) ≤ h˜MH(t|θ2) , whenever θ1 ≤ θ2 .
In particular, we have
h˜MH(t|θl) ≤ h˜MH(t|θ) ≤ h˜MH(t|θu) , ∀ t ,
which implies
h˜MH(t|θl) ≤ h˜(t) =
∫
h˜MH(t|θ) S˜MH(t|θ)
S˜(t)
f(θ) dθ ≤ h˜MH(t|θu) , ∀ t .
In other words, the population hazard h˜(t) lies within the area spanned
by the strongest component, h˜MH(t|θl) , and the weakest one,
h˜MH(t|θu) . This implies that h˜(t)→∞ as t→∞ . We can resume this
result for the general case of Lehmann families.
Proposition 1. Let S be an IFR Lehmann family based on hazard
function g(t) and suppose that g(t) ↑ ∞ as t → ∞ . Let f(λ) be a
probability density on (0,∞) . Let h(t) be the hazard function of the
mixture model with kernel S and mixing density f . If f is such that
supp{f} 63 0 , then h(t)→∞ as t→∞ .
Proof: S defines a proportional hazards model. Therefore λ1 ≤ λ2
implies that hλ1(t) ≤ hλ2(t) , ∀ t . Condition supp{f} 63 0 implies
that the minimum λl = min(supp{f}) is positive, λl > 0 . Since
hλl(t) ≤ h(t) , ∀ t , the result follows. 2
In particular, if 0 6∈ supp{f} , then the population hazard can neither
be DFR nor ultimately DFR. In other words, the condition 0 ∈ supp{f}
is necessary but not sufficient for a continuous mixture of IFR distribu-
tions be DFR. The condition means that the mixture model contains
components that are as strong as you like.
As an example, let us consider the mathematically easiest situation
of the uniform mixing distribution,
θ ∼ U [θl, θu] .
In this case it is possible to derive closed form solutions for S˜(t) and
h˜(t) . For t > 0 , we get the population survivor function,
S˜(t) =
∫ θu
θl
e−θt
n dθ
θu − θl =
1
(θu − θl)tn
(
e−θlt
n − e−θutn
)
,
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and the population hazard,
h˜(t) =
∫ θu
θl
θntn−1
e−θt
n
S˜(t)
· dθ
(θu − θl)
=
nt2n−1
e−θltn − e−θutn
∫ θu
θl
θe−θt
n
dθ
=
n
t
+ ntn−1
θle
−θltn − θue−θutn
e−θltn − e−θutn
=
n
t
− 1
e(θu−θl)tn − 1 h˜MH(t|θu) +
1
1− e−(θu−θl)tn h˜MH(t|θl) .
For t = 0 , we get S˜(t) = 1 , and since we assume n > 1 , we have
h˜MH(0|θ) = 0 , ∀ θ ,
and therefore h˜(0) = 0 . The above expression shows that h˜(t) ap-
proaches h˜MH(t|θl) as t gets large. So h˜(t) is at least ultimately strictly
monotonic increasing. Whether h˜(t) has a peak or not depends on the
wideness of the interval [θl, θu] . The population hazard will decrease
at some ages due to a frailty effect only if θ is allowed to vary enough.
This effect is shown in Figure 7.
It would be reasonable to consider also other distributions for θ
than the uniform. In such cases, it is much harder to get closed form
solutions for the population functions and numerical integration must
be used.
3.4 Multistage Carcinogenesis Models
We will now focus attention on the multistage model introduced in
Section 2.3. Recall the survivor function of this model,
S(t|n, ψ) = exp
{
−
∫ t
0
λI(x)FP (t− x) dx
}
,
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Figure 7: Population hazard function h˜(t) for the continuous multi-hit mix-
ture model where θ ∼ U [θl, θu] . For all curves, we set n = 3 and θl = 10−6 .
The upper bound was θu = c · θl for c = 3, 6, 9, . . . , 30 . The red dashed line
corresponds to h˜MH(t|θl) .
where
λI(x) = nνnN0xn−1 ,
FP (x) =
(β − δ − µ+∆)(β − δ − µ−∆)(e−∆x − 1)
2β[(β − δ − µ+∆)e−∆x − (β − δ − µ−∆)] ,
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with ∆ =
√
(β + δ + µ)2 − 4βδ . In the above expressions, n counts
the number of events needed for initiation of a cell, ν is the rate of
these events, β and δ are the birth and death rates of the fully initiated
cells, and µ is the rate at which cells out of the resulting clone are
transformed into cancer cells. These rates are resumed in the vector
ψ = (ν, β, δ, µ) . The remaining parameter N0 counts the number of
cells at risk.
In the sequel, we will introduce heterogeneity through the parame-
ters n and ψ . The motivation behind this is that carcinogenic agents
are supposed to have an impact on the biological parameters that con-
trol the initiation-promotion scheme. We will consider the biological
parameters one at a time. This assumes carcinogens that act as pure
initiators or pure promoters. For many known agents this is an oversim-
plification, since most substances are thought to act upon both stages
of carcinogenesis.
For simplicity, we will use interchangeably the notations S(t|n), S(t|µ)
etc. for the multistage model S(t|n, ψ) , and S(t) will denote the popu-
lation survivor function. The same remark applies to the hazard func-
tions. Finally, the number N0 will be considered fixed for the whole
population. This value is usually very large, and even if differences
among individuals certainly occur, we suppose them be negligible. If a
generalization seems appropriate, then rather to replace the fixed con-
stant N0 by a time dependent function N(t) as has been proposed by
many authors.
Initiation
The multistage model we consider here describes initiation as a se-
quence of n discrete events, namely rate limiting mutations, which lead
to a cell capable of accelerated growth. Similarly to the previous sec-
tion, it is a natural extension to let n be random. A biological mecha-
nism generating this kind of heterogeneity are germ line mutations of
the corresponding genes. This would lead to individuals starting life
with all cells in an intermediate stage. Mathematically, this means that
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the population survivor function is
S(t) =
k∑
i=1
piiS(t|ni, ψ) , (10)
where 0 < pii < 1 and pi1 + · · · + pik = 1 . The model determined by
(10) shows very much the same behaviour as the finite mixture model
of the multi-hit model (8) studied in Section 3.3. Again, the population
hazard typically has peaks as the different subgroups die out.
This model can be interpreted alternatively as a multiple pathway
model. Suppose that k pathways lead to cancer, where the cascades
differ only by the number of rate limiting events. If pii is the probability
a cell enters the cascade with ni events for initiation, then the survivor
function is given by (10). This model is illustrated in Figure 8.
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- T
Figure 8: Normal cells N are transformed into cancer cells T via different
cascades involving several stages of degenerated cells Ij . Pathway number i
involves ni mutational events and is taken with probability pii .
The second parameter related to initiation is the rate ν , and finite
as well as continuous distributions could be used to model its hetero-
geneity. Also in this case we get an expression resembling the structures
studied in the previous section,
S(t|ν) = e−νnG(t) ,
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where G(t) is convex, increases to infinity and does not depend on ν .
Therefore, we will not go further into details here and turn to the next
stage of carcinogenesis.
Promotion
Promotion is a complicated process and both genetic and epigenetic
factors seem to be involved. Therefore, heterogeneity can be due to
many different mechanisms. In the context of the multistage model,
there are two processes carcinogenic agents can influence: the growth
of initiated cells, and the malignant transformation of initiated cells.
Growth of initiated cells is modelled via a birth and death process
with birth rate β and death or differentiation rate δ . The parameter
of real interest, however, is the net growth rate, γ = β − δ .
The most natural approach is probably to model γ as a continuous
random variable with values in a given bounded interval [γl, γu] ⊂ R>0 .
For example, we can take a beta distribution with density
f(γ) =
1
B(a, b) · (γu − γl)a+b−1 (γ − γl)
a−1(γu − γ)b−1 ,
for γ ∈ [γl, γu] . As before, we get the population survivor function
S(t) =
∫ γu
γl
S(t|γ)f(γ) dγ . Also the population hazard can be repre-
sented in the usual form. With F (t) = 1− S(t) , we get
h(t) = lim
∆t↓0
F (t+∆t)− F (t)
∆tS(t)
=
1
S(t)
lim
∆t↓0
∫
F (t+∆t|γ)− F (t|γ)
∆t
f(γ) dγ
(?)
=
1
S(t)
∫
f(t|γ)f(γ) dγ
=
∫
h(t|γ)S(t|γ)
S(t)
f(γ) dγ .
The interchanging of limit and integral signs in step (?) can be justified
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by the dominated convergence theorem. The function
F (t|γ) = 1− e−
∫ t
0 λI(x)FP (t−x|γ) dx
is differentiable and strictly monotonic increasing in t for any γ ∈
[γl , γu] . Therefore, the function
g(∆t, γ) =
F (t+∆t|γ)− F (t|γ)
∆t
is continuous on the compact Ch = [0 , h] × [γl , γu] for any t, h > 0 .
This implies that on Ch the function g(∆t, γ) takes on its minimum
and maximum values,
0 < mh ≤ g(∆t, γ) ≤Mh <∞ , for (∆t, γ) ∈ Ch ,
and for example
∫
Mhf(γ)dγ = Mh . Thus, the bounded convergence
theorem applies. An example of such a model is shown in Figure 9.
Whether this structure can fit observed cancer incidence data or not
will be studied in Chapter 5.
Although the choice of a continuous distribution for γ seems intu-
itively natural, one can reasonably model γ by a discrete law. The
multistage model is a complicated model, and for continuous distri-
bution functions F (γ) we get a mathematically untractable situation.
Therefore, it is also interesting to assume a list 0 < γ1 < γ2 < · · · < γk
of possible values and work with the finite mixture model
S(t) =
k∑
i=1
piiS(t|γi) .
We will see in Chapter 5 that such models yield good fits in practical
applications. From the biological point of view, heterogeneity in γ has
tangible consequences only if the differences are large enough. So it is
crucial to know whether there are several groups with clearly changing
γ values, and a discrete model seems appropriate for this purpose.
Finally, note that similar considerations could be made using the
rate of malignant transformation, µ , instead of the pure growth rate
γ .
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Figure 9: Population hazard function h(t) for the continuous multistage
mixture model where γ is beta distributed with support [γl, γu] = [0.02, 0.2]
and shape parameters a = 0.8 and b = 2 . The lower left panel shows the
population survivor function S(t) (solid line) along with S(t|γl) and S(t|γu)
(dashed lines) . The lower right panel gives the density f(γ) .
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CHAPTER 4
Identifiability
Since the first appearance of stochastic carcinogenesis models in the
1950s, it has taken quite a long time for the scientific community to
understand the identifiability issue. Heidenreich (1996) showed that
for the classical TSCE model the survivor function (and therefore also
the hazard function) depends only on three parameters. This means
the biological parameters are non-identifiable from time to tumor data
alone. In Hanin and Yakovlev (1996) and Heidenreich et al. (1997)
identifiable combinations of the biological parameters are given. Sher-
man and Portier (1997) discuss ways to overcome non-identifiability.
They argue that either the parameter space must be reduced through
fixing of some parameters or additional constraints, or extra types of
data must be available. Hanin and Boucher (1999) and Hanin (2002)
discuss a modification of the modeling assumptions and identifiability
of this new model.
In this chapter we will give a series of identifiability results. First
we will consider the multistage model as given in Section 2.3. We will
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show that the results known from the TSCE model carry over to this
slightly more general case. Then we will discuss identifiability of the
mixture structure for selected finite mixture models.
4.1 The Multistage Model
Recall the definition of identifiability. Identifiability of a parametric
model {Pθ}θ∈Θ means that Pθ1 6= Pθ2 whenever θ1 6= θ2 . This is a
necessary condition for any sound statistical inference. The definition
says that we must make sure that two different parameter values cannot
yield the same probability measure.
The Number of Mutations for Initiation
Let us first focus on the number of mutations necessary for a cell to
be initiated: is n identifiable in the multistage model? Could a change
in n be compensated by some adjustment of the biological parame-
ters ν, β, δ, µ , leading to the same survivor function? The following
proposition shows that the behavior of S(t|n) at the origin is enough
to determine n.
Let S(t|n, ψ) be the survivor function of the multistage model given
in (2), where ψ = (N0, ν, β, δ, µ) denotes the vector of biological param-
eters.
Proposition 2. If for two parameter choices (n, ψ) , and (n˜, ψ˜) we
have S(t|n, ψ) ≡t S(t|n˜, ψ˜) , then n = n˜ .
Proof: Let us define the integral
I(t;n) :=
∫ t
0
λI(t− x;n)FP (x) dx .
Then, S(t|n, ψ) = exp{−I(t;n)} . We omit ψ , since the proof will
depend only on n , but not on the other biological parameters. We
calculate the first (n + 1) derivatives of I(t;n) with respect to t . For
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any n ≥ 1 ,
I ′(t;n) =
∫ t
0
n(n− 1)νnN0(t− x)n−2FP (x) dx ,
I(2)(t;n) =
∫ t
0
n(n− 1)(n− 2)νnN0(t− x)n−2FP (x) dx ,
...
I(n−1)(t;n) =
∫ t
0
n!νnN0FP (x)dx ,
I(n)(t;n) = n!νnN0FP (t) ,
I(n+1)(t;n) = n!νnN0F ′P (t) .
This shows that
I(k)(0;n) = 0 , for k = 0, 1, 2, . . . , n ,
and I(n+1)(0;n) 6= 0 if fP (0) = ddxFP (0) 6= 0. It follows from equation
(4) that fP (0) = µ > 0 .
We can now express the derivatives of the survivor function S(t|n)
using the derivatives of I(t;n) . In order to do this, let P(x1, . . . , xm)
denote a real polynomial in the variables x1, . . . , xm (of arbitrary de-
gree) without constant term. Using this notation, straightforward cal-
culation shows that
S(k)(t|n) = S(t|n) · P
(
I(t;n), I ′(t;n), . . . , I(k)(t;n)
)
,
for 1 ≤ k ≤ n− 1 , and
S(n)(t|n) = −I(n)(t;n)S(t|n)
+S(t|n) · P
(
I(t;n), I ′(t;n), . . . , I(n−1)(t;n)
)
,
S(n+1)(t|n) = −I(n+1)(t;n)S(t|n)
+S(t|n) · P
(
I(t;n), I ′(t;n), . . . , I(n)(t;n)
)
.
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Therefore,
S(k)(0|n) = 0 , for k = 1, 2, . . . , n ; and
S(n+1)(0|n) 6= 0 ;
for all n ∈ {1, 2, . . . } , where S(k) = dkS/dtk . The proposition is a
direct consequence. 2
In other words, to know how fast the survivor function S(t|n, ψ)
changes from its initial value S(0|n) = 1 as t increases is enough to
determine n . However, this result is of theoretical interest and cannot
be used in practice to estimate n .
The Biological Parameters
We will now consider the biological parameters ψ . As stated earlier,
the case n = 1 corresponds to the TSCE model, and it has been shown
in Hanin and Yakovlev (1996) that three functions of ψ are uniquely
determined by S(t|1, ψ) . This is intuitively plausible. Given n, the
intensity of initiation depends on the product N0νn, but not on N0
and ν individually. And the speed at which a clone of initiated cells
grows depends only on the difference β − δ , but not on the actual
pair β , δ . The line of reasoning given by Hanin and Yakovlev can be
generalized and the same result holds for any n ≥ 1 .
Lemma 1. Let (n, ψ) and (n˜, ψ˜) be two sets of parameters such that
S(t|n, ψ) ≡t S(t|n˜, ψ˜) . Then we have
νnN0FP (t;ψ) ≡t ν˜nN˜0FP (t; ψ˜) .
Proof: Note that by Proposition 2 both survivor functions, S(t|n, ψ)
and S(t|n˜, ψ˜) , must be based on the same number of stages, that means
n = n˜ . So we must show that if
I(t;n, ψ) ≡t I(t;n, ψ˜) , (11)
then
νnN0FP (t;ψ) ≡t ν˜nN˜0FP (t; ψ˜) .
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First, we transform I(t;n, ψ) via (n−1) repeated integrations by parts
into a n-fold integral,
I(t;n, ψ) = nνnN0
∫ t
0
(t− u1)n−1FP (u1) du1
= n(n− 1)νnN0
∫ t
0
(t− u1)n−2
∫ u1
0
FP (u2)du2 du1
...
= n!νnN0
∫ t
0
∫ u1
0
. . .
∫ un−1
0
FP (un) dun . . . du1 .
Next, we differentiate this expression n times with respect to t , to
obtain
dn
dtn
I(t;n, ψ) = n!νnN0FP (t;ψ) .
Application of these two steps to both sides of (11) proves the result.2
Lemma 1 generalizes a result by Hanin and Yakovlev that is used
to show non-identifiability of the two-stage model. The rest of their
argument can directly be applied to our case. More precisely, this
means that S(t|n, ψ) uniquely defines the three parameter combinations
p = β/(νnN0) ,
q = δ − β + µ ,
r = (β + δ + µ)2 − 4βδ .
In the sequel, we will therefore fix the two parameters N0 and δ to
get an identifiable model. Note that for example N0 =number of stem
cells in a given tissue and δ = 0 is an attractive model of this type.
We will also focus on γ = β − δ rather than on β itself, since it is the
growth advantage of initiated cells that is of real biological interest.
4.2 Identifiability of Mixture Models
We will now turn attention to the identifiability of the mixture structure
itself. Let us review briefly the necessary mathematical theory, which
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will be useful for the study of some mixture models of the multistage
model in the next section.
First of all, recall the definition of identifiability of a mixture model.
Let S(t|θ) be a survivor function depending on a parameter θ, and let
G be a set of probability distribution functions for θ . Then, G induces
the set of mixture models
S =
{∫
S(t|θ) dG(θ) ; G ∈ G
}
.
The family S is said to be identifiable with respect to G , if∫
S(t|θ)dG1(θ) ≡t
∫
S(t|θ) dG2(θ) =⇒ G1 ≡θ G2 , (12)
for all G1, G2 ∈ G . The definition says that if we know the population
survivor function
S(t) =
∫
S(t|θ) dG(θ) ,
then we know also the underlying mixing distribution G(θ) that has
generated it, at least within a given set of candidate distributions, G .
Very often we will simply say that the mixture model S(t) is identifi-
able with respect to G .
Let us first focus on the case of finite mixture models. In this
setting, the survivor functions are of the form
S(t) =
k∑
i=1
piiS(t|θi) ,
with weights such that 0 < pii < 1 , and
∑k
i=1 pii = 1 . The number
of components k ∈ N must not necessarily be fixed, and θ1, . . . , θk
are supposed to belong to a given countable set {ϑ1, ϑ2, ϑ3, . . . } . Let
S1(t) =
∑k
i=1 piiS(t|θi) and S2(t) =
∑k′
i=1 pi
′
iS(t|θ′i) be two mixture
models. The identifiability condition (12) now becomes
S1(t) ≡t S2(t) =⇒ {(pi1, θ1), . . . , (pik, θk)} = {(pi′1, θ′1), . . . , (pi′k′ , θ′k′)} .
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This means the summands of the mixture are uniquely determined
up to permutations. In order to eliminate this ambiguity, one must
require a supplementary condition. For example one can require that
ϑ1 < ϑ2 < ϑ3 < . . . .
In this work, we will use extensively the following result by Teicher
(1963):
Let {Si(t) ; i = 1, 2, . . . } be a family of survivor functions such that
1) Si(t) > 0 , ∀ t ≥ 0 , i = 1, 2, . . . ;
2) ∃ a ∈ R+ ∪ {∞} such that limt→a Si+1(t)Si(t) = 0 , i = 1, 2, . . . .
Then, the finite mixture model S(t) =
∑k
i=1 piiSi(t) is identifiable.
In order to establish the result, one first notes that for any positive
integer l , condition 2) implies
lim
t→a
Si+l(t)
Si(t)
= lim
t→a
Si+l(t)
Si+l−1(t)
· Si+l−1(t)
Si+l−2(t)
· · · Si+1(t)
Si(t)
= 0 .
Let now be given two identical finite mixtures
k∑
i=1
piiSni(t) ≡t
k′∑
j=1
pi′jSmj (t) , (13)
such that again
0 < pii, pi′j < 1 ,
k∑
i=1
pii =
k′∑
j=1
pi′j = 1 . (14)
Without loss of generality one can assume that
n1 < n2 < · · · < nk and m1 < m2 < · · · < mk′ .
If n1 6= m1 , again without loss of generality one can assume that
n1 < m1 . Then, by (13),
pi1 +
k∑
i=2
pii
Sni(t)
Sn1(t)
≡t
k′∑
j=1
pi′j
Smj (t)
Sn1(t)
,
70 CHAPTER 4. IDENTIFIABILITY
and letting t→ a one gets pi1 = 0 , in contradiction to (14). Therefore
n1 = m1 , and
pi1 − pi′1 +
k∑
i=2
pii
Sni(t)
Sn1(t)
≡t
k′∑
j=2
pi′j
Smj (t)
Sn1(t)
.
Letting again t→ a yields pi1 − pi′1 = 0 and equation (13) reduces to
k∑
i=2
piiSni(t) ≡t
k′∑
j=2
pi′jSmj (t) .
Repeating this argument a finite number of times it follows that
ni = mi , pii = pi′i , for i = 1, . . . ,min{k, k′} .
If k 6= k′ , e.g. k > k′ , then again by (13),
k∑
i=k′+1
pii︸︷︷︸
>0
Sni(t)︸ ︷︷ ︸
>0
≡t 0 ,
which is a contradiction. Thus, k = k′ . Teichers theorem is very useful
in practice, since it links identifiability to a condition that is easy to
check in many applications. In the sequel, we will refer to this result
as Teichers condition.
As we might expect, the continuous case is much more difficult to
treat. Results exist for special classes of distributions (like additively
closed families, the translation or the scale parameter family, Gaussian
distributions, exponential distributions), or for special models. Iden-
tifiability conditions from the general theory of integral equations are
given by Tallis and Chesson (1982). However, their results are hard to
apply in practice.
Finally, let us make a remark about identifiability in the classical
frailty modeling framework. Most of the frailty literature treats the
model
hind(t) = Z · h0(t) ,
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where the frailty Z is a non-negative random variable. This leads to a
population hazard
hpop(t) = h0(t) · E(Z|T > t) .
The model is non-identifiable unless assumptions on the amount of
variability among individuals are made. For example, one often puts
E(Z) = 1 (see Hougaard (1995)).
4.3 Finite Mixtures of the Multistage Model
Initiation
In Chapter 3 we proposed a finite mixture model based on the idea of
germ line mutations in cancer causing genes. The population survivor
function was
S(t) =
k∑
i=1
piiS(t|ni, ψ) .
The next proposition shows that such a mixture is identifiable.
Proposition 3. The family of finite mixture models induced by
{S(t|n, ψ) ; n = 1, 2, . . . }
is identifiable.
Proof: We show that Teichers condition is satisfied. Part 1) holds since
S(t|n, ψ) is the composition with an exponential function. In order to
check part 2), let us study the ratio
S(t|n+ 1, ψ)
S(t|n, ψ) = exp{−
∫ t
0
[λI(x;n+ 1)− λI(x;n)]FP (t− x) dx} .
The initiation incidence rates can be written recursively
λI(t;n+ 1) =
n+ 1
n
νtλI(t;n) .
Thus, for t > t1 := 2nν(n+1) ,
72 CHAPTER 4. IDENTIFIABILITY∫ t
0
λI(x;n) [n+1n νx− 1]FP (t− x) dx
≥ ∫ t1
0
λI(x;n)(n+1n νx− 1)FP (t− x) dx +
∫ t
t1
λI(x;n)FP (t− x) dx︸ ︷︷ ︸
:=Λ(t)
.
Since S(t|n, ψ) → 0 for t → ∞, we have Λ(t) → ∞ for t → ∞ . This
implies
S(t|n+ 1, ψ)
S(t|n, ψ)
t→∞−−−−−→ 0 .
2
Promotion
In Chapter 3 we also studied a finite mixture model that was motivated
by variation in γ . A similar result as above can be derived for this case.
Let there be a discrete set of γ-values, 0 < γ1 < γ2 < . . . . Note that
we consider δ = γi−βi as fixed, that is, we assume in fact that there is
an analogous sequence of βi . We will write ψ for the parameter vector
(n,N0, ν, δ, µ) .
Proposition 4. The family of finite mixture models induced by
{S(t|γi, ψ) ; i = 1, 2, . . . }
is identifiable.
Proof: We will first check Teichers condition in the case δ > 0 . We
have
S(t|γi+1, ψ)
S(t|γi, ψ) = exp
{
−
∫ t
0
λI(t− x)[FP (x|γi+1)− FP (x|γi)]dx
}
,
and the assumption δ > 0 implies that FP is improper and converges
to a limit a(γ, δ) < 1 as t→∞ . The value 1−a(γ, δ) is the probability
that a clone of initiated cells (generated by a single initiated cell at
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time t = 0) eventually dies out. The assumption γi+1 > γi implies that
a(γi+1, δ) > a(γi, δ) , and as a consequence∫ t
0
λI(t− x)[FP (x|γi+1)− FP (x|γi)]dx t→∞−−−−−→ ∞ .
Let us next consider the case δ = 0 , and thus γi = βi . The function
FP is in this case equal to
FP (x|β) = µ− µe
−(β+µ)x
µ+ βe−(β+µ)x
.
Using the mean value theorem we have
FP (x|βi+1)− FP (x|βi) = (βi+1 − βi) ∂
∂β
FP (x|β)
∣∣∣∣
β˜
,
where β˜ lies between βi and βi+1 . A direct calculation shows that
∂
∂β
FP (x|β) = µe
−(β+µ)x[(β + µ)x+ e−(β+µ)x − 1]
[µ+ βe−(β+µ)x]2
.
Therefore, we have
1) ∂∂βFP (0|β˜) = 0 ;
2) ∂∂βFP (x|β˜) is non-negative for all x ≥ 0 ; and
3) ∂∂βFP (x|β˜) asymptotically goes to 0 as x→∞ .
Let t0 be the (unique) maximum of ∂∂βFP (x|β˜) . It follows that∫ t
0
λI(t− x) ∂
∂β
FP (x|β˜) dx =
∫ t0
0
λI(t− x) ∂
∂β
FP (x|β˜) dx︸ ︷︷ ︸
>λI(t−t0)
∫ t0
0
∂
∂βFP (x|β˜) dx
+
∫ t
t0
λI(t− x) ∂
∂β
FP (x|β˜) dx︸ ︷︷ ︸
>0
.
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This shows that
(βi+1 − βi)
∫ t
0
λI(t− x) ∂
∂β
FP (x|β˜) dx t→∞−−−−−→ ∞ ,
which completes the proof. 2
The same ideas could be applied to parameter µ . Though the bi-
ological interpretation of such a frailty model would be different, tech-
nically no new issues arise, and similar results can be established.
Counterintuitive Properties
The proof of proposition 3 reveals the somehow counterintuitive fact
that S(t|n+1, ψ) > S(t|n, ψ) does not hold for all t . Logically, individ-
uals needing n+ 1 events for initiation must have a higher probability
to survive up to age t than those needing only n such events. And of
course, the model does have this property for all reasonable lifetimes
t . However, far in the tails the two survivor functions cross. Let us
illustrate this for the simpler multi-hit model SMH(t) given in Section
2.2. Recall the survivor function
SMH(t|n) = exp{−N0νntn} .
We do have as expected SMH(t|n) ≤ SMH(t|n + 1) for t ∈ [0, ν−1]. But
if t > ν−1 , then the order is reversed. Note that ν is interpreted as
a mutation rate per year, i.e. ν is a very small number (of about the
order 10−5).
The inconsistent behaviour in the tails is a consequence of the ap-
proximation used to derive the survivor function SMH(t) . To illustrate
this, let us consider the exact solution for a multi-hit process with n
hits . Let Xi denote the waiting time for a single cell to pass from com-
partment i−1 to compartment i . We assume the sequence X1, . . . , Xn
be independent and identically exponentially distributed E(ν) . Then,
the waiting time for a single cell to be transformed into a tumor cell,
Tn = X1 + · · ·+Xn ,
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is gamma distributed with shape parameter n and scale parameter 1/ν .
Let there beN0 cells at risk in the organism. We assumeN0 be constant
over time and suppose the different cells at risk to behave independently
of one another. Then, we can attribute such a waiting time to every
of the N0 cells and get the sequence of independent and identically
distributed random variables T 1n , . . . , TN0n . With this notation, the
survivor function of the organism for tumor onset is
S˜MH(t|n) = P(min
j
T jn > t) = P(Tn > t)
N0 .
This notation shows that
S˜MH(t|n) < S˜MH(t|n+ 1) , ∀ t > 0 .
The survival probability is indeed higher if more hits are needed. The
inconsistency disappears.
If we want to study the fraction
S˜MH(t|n)
S˜MH(t|n+ 1)
=
P(Tn > t)N0
P(Tn+1 > t)N0
,
we see that it is enough to consider a single cell, that is the fraction
with N0 replaced by 1 . Since Tn is gamma distributed, we get
P(Tn > t)
P(Tn+1 > t)
=
nΓ(n, νt)
Γ(n+ 1, νt)
,
where
Γ(n, t) =
∫ ∞
t
e−xxn−1 dx
is the upper incomplete gamma function. Since n is an integer, we have
the representation
Γ(n, t) = (n− 1)! e−t
n−1∑
k=0
tk
k!
.
Therefore, we get
P(Tn > t)
P(Tn+1 > t)
=
1 + νt+ · · ·+ (νt)n−1/(n− 1)!
1 + νt+ · · ·+ (νt)n/n! ≤ 1 , ∀ t ≥ 0 ,
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with equality if and only if t = 0 . The above expression implies also
that
S˜MH(t|n)
S˜MH(t|n+ 1)
t→∞−−−−−→ 0 , ∀n .
Applying Teichers condition, we have shown the following
Proposition 5. The family of finite mixture models induced by
{S˜MH(t|n) ; n = 1, 2, . . . }
is identifiable.
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CHAPTER 5
Application to Data
5.1 Data Description
We will now apply our mixture models to human cancer incidence data.
Such data typically shows a sharp increase in the number of cases from
about the age of forty, reaches a peak around the age of eighty, and
decreases for the very old. This effect can be explained by the dy-
ing out of the high-risk group of the population. In order to study
this phenomenon, we need incidence data from a population with in-
dividuals that have lived under comparable conditions. Therefore, we
need birth cohort rather than cross-sectional data. We will investigate
lung cancer and colon cancer data for European Americans born in the
1880s, 1890s, 1900s, and 1920s from Herrero-Jimenez et al. (2000) and
Morgenthaler et al. (2004).
The data actually consists of population counts from 1930 to 1991,
of mortality tables from lung cancer for the same period, and of mortal-
ity tables from colon cancer from 1958 to 1991. In all cases the counts
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were grouped into five year age intervals: 0-4 years, 5-9 years, 10-14
years and so on. For simplicity we assume these binned counts to be
equally distributed within their age groups to obtain the cohort data.
In order to apply a carcinogenesis model, we must adjust the data
for the confusion of mortality and incidence. The data at hand gives
only site specific mortality, while the stochastic models discussed in
Chapters 2 to 4 describe incidence. Mortality does reflect incidence,
but will underestimate the number of cancer cases. This is a minor
issue for highly fatal tumors, where mortality is approximately equal
to incidence. But in many other cases, there is relatively efficient treat-
ment available, and some kind of correction must be applied. Let o˜i be
the number of deaths during the interval [ti, ti+1) . Then, we will simply
multiply o˜i by a constant to obtain the observed incidence, oi = c · o˜i .
For lung cancer, patients still have very poor prospects. In Stewart
and Kleihues (2003) the worldwide numbers of lung cancer cases and
deaths per year are given. These counts, reproduced in Table 1, can be
used to obtain a reasonable value for c .
Males Females
Incidence 901 337
Lung Cancer
Mortality 810 292
Table 1: Worldwide numbers of lung cancer cases and deaths in thousands
per year given by the WHO (Stewart and Kleihues (2003)).
This leads to the sex specific correction factors cm = 1.11 , cf = 1.15 .
These numbers are consistent with survivor probabilities given in US
registries. We obtain the adjusted observed incidence data shown in
Table 2. The corresponding hazard curves are given in Figure 10. Note
that in Table 2 the population at risk for the 1890s, the 1900s, and
the 1920s group is not strictly decreasing. This is due to immigration.
The data in Table 2 is, however, the best approximation to human
cohort data we could get. Whenever the increase in the at risk sets is
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Figure 10: Observed lung cancer incidence corresponding to the data given
in Table 2. The raw hazard estimates are calculated λˆi = oiri(ti+1−ti) , where
ri counts the population at risk and oi the number of cases over the interval
[ti, ti+1) .
incompatible with a method, we will restrict the analysis to the 1880s
birth cohort.
The case of colon cancer is more difficult to treat. The cure rate
is much higher, and the treatments evolved considerably over the time
span we consider. In Herrero-Jimenez et al. (2000) this problem is
discussed. These authors estimate the survival rates for colon cancer
by age and year of diagnosis. Their results are given in Table 3. Let
o˜(h, t) denote the number of deaths from birth cohort h at age t . We
can then estimate the actual number of colon cancer cases as
o(h, t) = o˜(h, t)/(1− S(h, t)) ,
where S(h, t) is the relative colon cancer survival rate for age cohort
h at age t (read out of Table 3). We get the adjusted colon cancer
incidence data shown in Table 4 and Figure 11.
Let us finally mention that often only cross-sectional data is avail-
able. In this case, one can take the multistage model as age-specific
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Males
1880s 1890s 1900s 1920s
Age At risk Cases At risk Cases At risk Cases At risk Cases
[0, 5) 49475170 68
[5, 10) 51880815 90
[10, 15) 52755426 128
[15, 20) 53422234 256
[20, 25) 46424286 274 52475231 316
[25, 30) 44910182 378 54795743 428
[30, 35) 40683682 407 44667053 637 55221754 1206
[35, 40) 41873241 1083 45202500 1687 55294801 3673
[40, 45) 37177005 1677 39700013 2699 45707353 4739 55008545 10906
[45, 50) 35222529 3362 39592494 7163 44518021 12610 54123447 26223
[50, 55) 33219575 6927 37969964 16161 42964495 27904 52411957 51993
[55, 60) 30583428 13659 36270150 31740 40410105 51346 49739071 87606
[60, 65) 28701833 23011 32952183 50956 36610956 80189 46125810 130597
[65, 70) 25400588 32468 28347996 67129 31535474 104682 41230912 164468
[70, 75) 20249992 35839 22607010 71395 25621407 112494 33816110 169079
[75, 80) 14526850 30718 16288426 62592 19258373 100255
[80, 85) 8851802 20525 10314523 42708 12539867 68564
[85, 90) 4247329 10508 5365053 22220 6136070 31448
[90, 95) 1527841 3676 2080776 7549 2284233 9505
[95, 100) 373936 862 503896 1485
[100, 105) 54275 107 66610 167
Females
Age 1880s 1890s 1900s 1920s
At risk Cases At risk Cases At risk Cases At risk Cases
[0, 5) 47616208 54
[5, 10) 50281978 64
[10, 15) 51160245 89
[15, 20) 52612257 144
[20, 25) 47573246 170 53078675 171
[25, 30) 45740263 237 55292676 207
[30, 35) 40618853 328 44994177 389 55700064 474
[35, 40) 40880241 591 45260577 776 55881276 1451
[40, 45) 34845993 877 38463333 1120 45620766 1415 55792798 4342
[45, 50) 32927685 1291 38474741 2031 44891751 2669 55338368 10979
[50, 55) 30962992 2146 37936954 3312 44213190 4522 54388589 22500
[55, 60) 29497353 3539 37563639 4781 42985653 7912 52875595 40645
[60, 65) 28978869 4998 35826007 6688 41114123 13679 51045641 65700
[65, 70) 27200715 6387 33221776 9238 38408131 22477 48937816 89287
[70, 75) 23757908 7258 29466608 12445 34742896 31152 43665837 97489
[75, 80) 19234172 7235 24495607 14921 30012287 37272
[80, 85) 13755533 6667 18597769 14772 23620919 34490
[85, 90) 8080774 5054 12090697 11558 14998028 20476
[90, 95) 3704766 2722 6116973 6168 7288050 8483
[95, 100) 1206871 932 1903266 1789
[100, 105) 242950 155 329783 261
Table 2: Lung cancer incidence data from European Americans.
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Year of Ages
diagnosis 0-44 45-54 55-64 65-74 75+ 100+
m 0.58 0.62 0.65 0.66 0.59 0.03
1990s
f 0.59 0.65 0.62 0.64 0.60 0.04
m 0.49 0.59 0.59 0.60 0.57 0.03
1980s
f 0.58 0.56 0.56 0.57 0.55 0.04
m 0.47 0.48 0.48 0.48 0.44 0.03
1970s
f 0.58 0.50 0.50 0.48 0.46 0.04
m 0.50 0.45 0.45 0.44 0.37 0.03
1960s
f 0.50 0.48 0.48 0.47 0.42 0.04
m 0.42 0.46 0.40 0.38 0.32 0.03
1950s
f 0.46 0.46 0.46 0.42 0.38 0.04
m 0.27 0.33 0.29 0.21 0.17 0.03
1940s
f 0.34 0.34 0.35 0.28 0.24 0.04
m 0.30 0.27 0.20 0.09 0.00 0.03
1930s
f 0.25 0.17 0.18 0.11 0.07 0.04
Table 3: Relative survival rates for colon cancer by age and year of diagnosis
from Herrero-Jimenez et al. (2000).
baseline hazard h(t) . An adjustment for the birth year i and for the
year of diagnosis j must then be applied. In Luebeck and Moolgavkar
(2002), the model hij(t) = bicjh(t) is considered. In particular, these
authors investigate the evolution of bi and cj over time.
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Males
1880s 1890s 1900s 1920s
Age At risk Cases At risk Cases At risk Cases At risk Cases
[25, 30) 54795743 438
[30, 35) 55221754 1034
[35, 40) 55294801 2056
[40, 45) 55008545 4494
[45, 50) 44518021 5731 54123447 8195
[50, 55) 42964495 12451 52411957 16760
[55, 60) 36270150 14761 40410105 18184 49739071 29530
[60, 65) 32952183 24894 36610956 31072 46125810 57887
[65, 70) 25400588 24000 28347996 32382 31535474 43153 41230912 80411
[70, 75) 20249992 35138 22607010 43779 25621407 58148 33816110 105098
[75, 80) 14526850 29669 16288426 40205 19258373 56166
[80, 85) 8851802 24846 10314523 38042 12539867 60703
[85, 90) 4247329 14600 5365053 24143 6136070 36335
[90, 95) 1527841 6647 2080776 13662 2284233 16024
[95, 100) 373936 1657 503896 3324
[100, 105) 54275 137 66610 162
Females
1880s 1890s 1900s 1920s
Age At risk Cases At risk Cases At risk Cases At risk Cases
[25, 30) 55292676 439
[30, 35) 55700064 1281
[35, 40) 55881276 2885
[40, 45) 55792798 5667
[45, 50) 44891751 8061 55338368 9830
[50, 55) 44213190 15909 54388589 17151
[55, 60) 37563639 17446 42985653 22962 52875595 26882
[60, 65) 35826007 29722 41114123 32946 51045641 42324
[65, 70) 27200715 27986 33221776 36678 38408131 45614 48937816 58616
[70, 75) 23757908 39534 29466608 49928 34742896 59122 43665837 84852
[75, 80) 19234172 38550 24495607 52121 30012287 65247
[80, 85) 13755533 36850 18597769 55591 23620919 76709
[85, 90) 8080774 26956 12090697 43701 14998028 60756
[90, 95) 3704766 13712 6116973 28950 7288050 37817
[95, 100) 1206871 4371 1903266 9335
[100, 105) 242950 406 329783 559
Table 4: Colon cancer incidence data from European Americans.
5.2 Finite Mixtures and Lung Cancer Data
We will now apply our mixture models to the lung cancer data shown
above. In a first step, we consider the easiest situation of a two com-
ponent mixture. Most of the time, we use the γ-frailty model with
survivor function
S(t) = pilS(t|γl) + (1− pil)S(t|γu) , (15)
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Figure 11: Observed lung cancer incidence corresponding to the data given
in Table 4.
where 0 < γl < γu , 0 < pil < 1 , and S(t|γ) is the survivor function
(2) of the multistage carcinogenesis model given in Section 2.3. Model
(15) will serve to illustrate the main issues concerning parameter esti-
mation, and its choice is somewhat arbitrary. Other frailty models will
be considered later.
Recall the complete list of parameters of model (15): N0 , the num-
ber of cells at risk; n , the number of mutations necessary to initiate a
cell; ν and µ , the rates of initiating mutations and malignant transfor-
mation; γl and γu , the net growth rates of initiated cells; δ , the death
rate of initiated cells; and pil , the proportion of the population with
low net cell growth rate . In order to guarantee identifiability, we will
fix N0 and δ . Since the parameters are biologically meaningful, we can
find reasonable values for them in the literature. But we must keep in
mind that all estimates will be conditional given N0 and δ . The former
of these two acts as a scale parameter. Changes in N0 are compensated
by ν , and qualitatively no different effects arise for altering N0 values .
The role of δ , however, is more difficult to assess, and it is reasonable
to perform some sensitivity analysis.
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In order to get stable estimates, we will usually fix some more pa-
rameters. For model (15) for example, we will estimate (pil, ν, γu, µ) for
several choices of previously specified n and γl . Numerical optimiza-
tion will be done using the simplex method described in Nelder and
Mead (1965). The procedure is implemented in the R function optim.
This method does not require derivatives, which is an important fea-
ture in our case, since S(t) is a rather complicated function in terms of
the biological parameters. The simplex method is relatively slow, but
robust.
Note that the parameters we estimate have a restricted domain of
definition,
(pil, ν, γu, µ) ∈ (0, 1)× R+ × (γl,∞)× R+ .
We will use suitable transformations to respect these constraints. More
precisely, numerical optimization will always be performed using the fol-
lowing reparametrization: p˜il = logit(pil) , dγ˜ = log(γu − γl) ,
ν˜ = log10(ν) , and µ˜ = log10(µ) . Recall the definition of the logit-
function,
logit: (0,1) −→ R
x 7−→ ln
(
x
1−x
)
,
which we used to transform the probability pil .
5.2.1 Maximum Likelihood
The first procedure we consider is maximum likelihood estimation. In
order to derive the likelihood function for our case, it is useful to rep-
resent the cohort data on a time axis as in Figure 12.
We see that the cohort is made up by r0 individuals. But instead of the
lifetimes y1, . . . , yr0 , we only know how many persons failed in [ti, ti+1)
due to cancer, namely oi , and how many failed due to competing causes,
namely
ci = ri − ri+1 − oi .
We will treat these cases as right censorings. Thus, we get two types of
likelihood contributions from the totally oi+ci failures during [ti, ti+1) :
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Figure 12: Our data structure. At fixed time points 0 ≤ t0 < t1 < · · · < tN
we know the population at risk r0 , r1 , . . . , rN , while o0 , o1 , . . . , oN denote
the failures due to cancer in the intervals between two consecutive time points.
the oi individuals having a cancer give each a factor (S(ti)− S(ti+1)) ,
while the ci censored individuals contribute S(ti) . This means, we
obtain the likelihood
L(pil, ν, γu, µ|N0, δ, n, γl) =
N∏
i=0
(
S(ti)− S(ti+1)
)oi
S(ti)ci .
This means we assume independent and noninformative censoring. We
must adopt some convention for tN+1 . We can either set tN+1 = ∞ ,
in which case S(tN+1) = 0 , or we can set tN+1 equal to some artificial
finite endpoint. Note that in our applications both possibilities yield
virtually the same results. But in some theoretical contexts it may
be a necessary assumption that tN+1 < ∞ . Finally, we always set
rN+1 = 0 .
In order to estimate the biological parameters, we will use the pre-
viously introduced parametrization. That means we maximize the log-
likelihood
l(p˜il, ν˜, dγ˜, µ˜) =
N∑
i=0
{
oi log
(
S(ti)− S(ti+1)
)
+ ci logS(ti)
}
.
Let us consider the lung cancer incidence data from the males 1880s
cohort. Although our numerical optimizer converges, we observe a
strange behaviour of the MLE. Figure 13 shows the data along with
the models corresponding to the MLE, the LSE, and the starting value
of the numerical optimization. As we can see, the MLE fails completely
to catch the behaviour of the observed incidence at old ages; only the
first few data points are well fitted. Convergence to this model seems
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even more astonishing when we consider the initial model. The chosen
starting value is far away from the data in terms of fit, but it is close
to the observed hazard in terms of shape. Furthermore, the model
corresponding to the LSE fits the observed hazard very closely. This
shows that the parametric family we apply to the data does indeed
contain models that can fit. But in this example, likelihood and fit
do not measure the same thing. The huge discrepancy, however, is
intriguing.
The strange behaviour of the MLE is caused by several effects. One
aspect is model mis-specification in relation with the special metric
used in likelihood based inference. The data is not really generated
by our multistage model, while the MLE corresponds to the survivor
function that minimizes the Kullback-Leibler distance to the observed
empirical survivor function. But this is a very special metric and can
produce obviously strange results in some cases.
Another point concerns the way we look at our data. In carcino-
genesis, it is natural to work with hazard curves. On the population
level, site specific cancer is a rare disease and survivor functions are ex-
tremely flat over the whole lifespan. Therefore, plots of survivor func-
tions would be very hard to interpret; the corresponding hazard curves
on the other hand show interesting patterns. The LSE is optimal with
respect to fitting the observed hazard, while the likelihood we have in-
troduced above uses the survivor function as main ingredient. Because
h(t) = −d logS(t)/ dt , two hazard curves can be markedly different,
although the corresponding survivor functions are rather close.
The above mentioned points are just two aspects of the problem.
We investigate other issues in more detail below.
The Likelihood Surface
In mechanistic modeling, likelihood based inference is often difficult
due to local maxima and/or low curvature around the maxima. Both
problems apply to our case. Our likelihood-surface is multimodal be-
cause the different biological parameters compete. This problem can
be avoided by extensive use of the available biological knowledge. If we
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Figure 13: Lung cancer data from the males 1880s cohort along with esti-
mated models of the form (15). We fixed N0 = 1010 , δ = 0 , n = 2 γl =
10−4 , and used the initial value p˜il = logit(0.97) , dγ˜ = log(0.2) , ν˜ = −6.5
and µ˜ = −5 .
have good starting values and restrict attention to biologically reason-
able intervals, then the likelihood surface is unimodal in that domain.
The second problem is more difficult to treat. Even for identifiable
parameters the likelihood surface is often extremely flat around its
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maximum. Figure 14 gives the contour plot of the log-likelihood for
a reduced parameter space. That is we take model (15), but fix all pa-
rameters except ψ = (p˜il, µ˜) . We see that the log-likelihood surface has
a ridge. While µ˜ can be estimated relatively precisely, there is much
more uncertainty about p˜il . The log-likelihood values of the estimates
in Figure 14 are
l(ψˆML) ' −1.338 · 106 , l(ψˆLS) ' −1.355 · 106 .
This shows that on a relative scale, the two are extremely close,
l(ψˆML)/l(ψˆLS) ' 0.99 .
But if we do a likelihood ratio test for ψˆLS against ψˆML , we get
2(l(ψˆML)− l(ψˆLS)) ' 32600 qχ22(0.999) ≈ 13.8 ,
which means that ψˆML is significantly different from ψˆLS . A 95% con-
fidence region determined by a likelihood-ratio test is given in Fig-
ure 15. This set is actually extremely small; expressed in the natural
parametrization (pil, µ) it is contained in the rectangle [0.944, 0.947] ×
[8 · 10−7, 8.5 · 10−7] .
Heavy Censoring
The most important reason that leads to the failure of the MLE in
our application, however, is the heavy censoring. We deal with human
cancer incidence data. This means we consider a rare event, and most
members of the population fail from competing causes. In the data set
we are considering there are tens of millions individuals at risk at the
first time points, but only some tens of thousands at the last one.
In order to illustrate the impact of censoring, we will construct
a sequence of artificial data sets that lead to the same raw hazard
estimates, but differ in the degree of censoring. As before, we note by
(ri, oi) the real data set. Let us define the points (r˜ki , o˜ki ) by
r˜ki = 10
6 − i · k104 , and o˜
k
i
r˜ki
=
oi
ri
. (16)
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Figure 14: Contour plot of the log-likelihood surface (left panel) and of the
residual sums of squares surface. The parameter space is reduced such that
only p˜il and µ˜ are estimated. The other parameters are fixed as in Figure
13 . Additionally, we set γu = 0.192 and ν = 2.43 · 10−7 , which are their
respective least squares estimates from the unrestricted case.
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Figure 15: Contour plot of the log-likelihood surface. The red dashed line
gives the border of a 95% confidence region determined by a likelihood-ratio
test.
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Figure 16: Hazard curves corresponding to the MLEs for the data sets con-
structed according to (16). The right panel shows the residual sums of squares
between the models and the raw hazard estimates as a function of the coeffi-
cient of variation of the at risk sets. Note that for the real data set we have
cv(r0, . . . , r12) ≈ 0.77 .
That is we start with a population of size 106 and suppose that during
every time interval exactly k104 individuals die - either due to cancer
or due to competing causes. We then fit model (15) by maximum
likelihood as before (we consider again the four parameters p˜il ν˜ dγ˜ µ˜
as unknown). Figure 16 gives the estimated models for k = 1, . . . , 8 .
The MLE does indeed behave better for small k than for large k . We
also calculated the residual sums of squares (RSS) for these models,
which seems to increase exponentially with the coefficient of variation
of the r˜ki sequence,
cvk =
sd(r˜k0 , . . . , r˜k12)
mean(r˜k0 , . . . , r˜k12)
.
The above example shows that the MLE is dominated by the points
corresponding to large at risk sets. We have also seen that the LSE,
on the contrary, works fine, since it attributes equal weight to all age
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intervals. This makes one wonder whether a weighted least squares
approach would suffer from the same problem as the MLE. If we give
for example weights proportional to the population at risk, would the
LSE break down as well? The answer to this question is clearly no.
Considering Figure 13 once again, we realize that there is a model that
fits all the data points very accurately. This model will be extremely
good even if we downweight the contribution to the RSS of the points
at high ages. Any weighted least squares approach will select a model
that is very close to the standard LSE.
5.2.2 Analytic Graduation
The least squares estimate in the previous illustrations was obtained by
analytic graduation described in Section 1.3.4. This method works very
well in our application. Therefore, we will use this technique to analyze
the different data sets introduced at the beginning of this chapter. In a
first part, we will continue to use the model with γ-frailty. But later on,
we will consider heterogeneity in other biological parameters as well.
Random Growth Advantage
Let us consider model (15) more closely. We mentioned earlier that we
fixed the net growth rate of the low risk group, γl , in order to get stable
estimates. The model corresponding to ψˆLS fitted the observed hazard
for the lung cancer incidence data (males 1880s cohort) extremely ac-
curately. But we must keep in mind that ψˆLS is conditional on γl .
To assess the sensitivity of ψˆLS to γl , we repeated the estimation for
several γl values. The result is given in Table 5. It turns out that we
get good fits only when γl is small enough. This means that the large
majority of the population must be at very low cancer risk. Conse-
quently, the observed peak in the hazard curve is due to the dying out
of the group of proportion 1−pil with net growth rate γu . Table 5 also
gives the results for several δ , but this seems to have a minor impact
on parameter estimates.
We will now apply model (15) to the lung cancer incidence data from
all cohorts and both sexes. The model is flexible enough to fit all the
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δ γl pˆil γˆu νˆ µˆ RSS
0 10−5 0.976 0.193 2.43 · 10−7 2.33 · 10−6 3.07 · 10−10
0 10−4 0.976 0.192 2.43 · 10−7 2.43 · 10−6 3.09 · 10−10
0 10−3 0.976 0.192 2.43 · 10−7 2.35 · 10−6 3.09 · 10−10
0 0.01 0.976 0.194 2.44 · 10−7 2.20 · 10−6 3.16 · 10−10
0 0.1 0.664 0.917 2.17 · 10−8 1.57 · 10−4 1.08 · 10−7
0 0.2 0.969 0.625 2.14 · 10−8 3.95 · 10−5 6.88 · 10−8
0.01 10−4 0.976 0.193 2.49 · 10−7 2.22 · 10−6 3.09 · 10−10
0.05 10−4 0.975 0.212 2.60 · 10−7 8.20 · 10−7 3.94 · 10−10
0.1 10−4 0.976 0.192 2.30 · 10−7 1.55 · 10−6 3.09 · 10−10
Table 5: Parameter estimates ψˆLS (transformed back into the natural
parametrization) for several choices of γl and δ . For all cases we fixed n = 2
and N0 = 1010 .
data sets, as shown in Figure 17 and Table 6. The clear evolution of the
hazard curves between the 1880s cohorts and the 1920s cohorts must
be due to an increased exposure to risk factors, presumably smoking.
These changes are reflected in the growing estimated proportions of
high risk individuals, 1−pˆil . A similar evolution of the other parameters
is less clear when we consider both sexes. But the growth rates γˆu
seem to counteract the mutation rates νˆ , µˆ . The main feature that
determines the estimates is the peak in the observed hazard. Therefore,
the 1920s cohorts do not contain enough information at high ages to
obtain reliable ψˆLS values. At best, we can get an indication for the
possible continuation of a trend observed in the 1880s to 1900s cohorts.
In order to assess the accuracy of the estimates, we use projections
of a joint confidence region rather than marginal confidence intervals.
In other words, we determine a confidence region C ⊂ R4 , and then we
look at projections of C on the six two-dimensional parameter planes
spanned by the four parameter axis. This reveals the strong depen-
dencies between the different parameters. The asymptotic confidence
region we get for the males 1880s cohort is shown in Figure 18. Again
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Figure 17: Two component mixture model with frailty γ fitted to the lung
cancer incidence data.
we see the negative relationship between γu and the mutation rates
ν, µ . The set C can be used to construct a confidence band for the
hazard curve itself. Figure 19 shows all the incidence functions corre-
sponding to parameter values contained in C . The confidence band we
get reflects basically the variability present in the raw hazard estimates
λˆi .
Cohort Males Females
pˆil γˆu νˆ[10−7] µˆ[10−6] pˆil γˆu νˆ[10−7] µˆ[10−6]
1880s 0.976 0.192 2.4 2.4 0.998 0.128 8.5 0.9
1890s 0.968 0.172 3.2 4.5 0.995 0.144 4.3 2.4
1900s 0.962 0.166 3.6 5.5 0.992 0.166 4.8 1.5
1920s 0.920 0.188 1.9 7.6 0.977 0.199 2.7 3.3
Table 6: Parameter estimates corresponding to the curves in Figure 17. The
fixed parameters are N0 = 1010 , δ = 0 , γl = 10−4 and n = 2 .
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Figure 18: Projections of an asymptotic 95% confidence region for ψ .
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Figure 19: Asymptotic 95% confidence band for the hazard function for lung
cancer incidence for the males 1880s cohort. The black line gives the raw
hazard estimates λˆi along with the corresponding asymptotic 95% confidence
intervals.
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Cohort Males Females
pˆil γˆ νˆ[10−7] µˆu[10−5] pˆil γˆ νˆ[10−6] µˆu[10−6]
1880s 0.977 0.150 2.7 1.4 0.995 0.074 2.4 3.0
1890s 0.967 0.152 3.4 1.1 0.993 0.081 2.5 2.2
1900s 0.960 0.146 3.8 1.3 0.991 0.138 0.5 5.5
1920s 0.932 0.174 2.2 1.2 0.981 0.172 0.3 8.3
Table 7: Parameter estimates corresponding to the curves in Figure 20. The
fixed parameters are N0 = 1010 , δ = 0 , µl = 10−10 and n = 2 .
Random Rate of Malignant Transformation
Up to now, we have modelled heterogeneity in promotion only via dif-
ferent growth rates of initiated cells. But we can also imagine promoters
that increase mutation rates. In this case, we consider µ be random
with states µl and µu . This leads to a model with survivor function
S(t) = pilS(t|µl) + (1− pil)S(t|µu) , (17)
where 0 < µl < µu . We assume n,N0, ν, δ and γ to be equal for both
components, S(t|µl) and S(t|µu) , and for numerical optimization we
use the parametrization
p˜il = logit(pil) , γ˜ = log(γ) , ν˜ = log10(ν) , µ˜ = logit
(
log10(µu)
log10(µl)
)
.
Table 7 and Figure 20 summarize the estimates we get in this case.
Model (17) can reproduce the lung cancer incidence data very accu-
rately. This is a typical feature of multistage modeling: many different
models fit the data equally well. But the biological interpretation is not
the same for the two models (15) and (17). Therefore, model selection
must be based on biological considerations and cannot be achieved by
statistical means alone. Note that we get good fits only as long as µl is
small enough. So we again have a large group that is virtually immune,
and a small minority at high risk.
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Figure 20: Two component mixture model with frailty µ fitted to the lung
cancer incidence data.
Random Number of Mutations for Initiation
Finally, it is natural to consider a population in which a part has already
inherited some mutations needed for initiation of normal stem cells.
The resulting population survivor function is
S(t) = pi1S(t|n1) + (1− pi1)S(t|n2) , (18)
with 1 ≤ n1 < n2 . In this case, we will estimate p˜i1 , γ˜ , ν˜ and
µ˜ = log10(µ) for several fixed combinations (n1, n2) . The results are
summarized in Table 8. As expected, the number of mutations needed
for initiation strongly influences the estimates νˆ . But also γˆ and pˆi1 are
affected, which is more surprising. This means that for a given cohort,
the estimates (pˆi1, γˆ, νˆ, µˆ)|(n1, n2) differ markedly. Only some of these
combinations might biologically be reasonable.
Competing Related Risks
Recall the approach proposed by Morgenthaler et al. (2004) to intro-
duce population heterogeneity. These authors introduce two new pop-
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Cohort n1 n2 pˆi1 γˆ νˆ µˆ RSS
males
1880s 1 2 0.038 0.133 2.0 · 10−11 9.1 · 10−6 1.2 · 10−9
1890s 1 2 0.039 0.127 4.7 · 10−11 9.5 · 10−6 2.6 · 10−9
1900s 1 2 0.046 0.129 5.6 · 10−11 8.7 · 10−6 3.0 · 10−9
1920s 1 2 0.208 0.149 6.6 · 10−12 9.6 · 10−6 3.6 · 10−10
females
1880s 1 2 0.006 0.075 1.1 · 10−9 3.5 · 10−6 1.7 · 10−10
1890s 1 2 0.008 0.098 1.1 · 10−10 1.0 · 10−5 2.3 · 10−11
1900s 1 2 0.010 0.133 8.8 · 10−11 2.9 · 10−6 5.9 · 10−11
1920s 1 2 0.189 0.163 3.0 · 10−12 5.2 · 10−6 2.3 · 10−11
males
1880s 2 3 0.025 0.184 7.6 · 10−7 3.7 · 10−6 3.0 · 10−10
1890s 2 3 0.034 0.161 9.9 · 10−7 8.2 · 10−6 1.6 · 10−9
1900s 2 3 0.040 0.147 1.2 · 10−6 1.3 · 10−5 1.0 · 10−9
1920s 2 3 0.069 0.174 7.0 · 10−7 1.2 · 10−5 9.2 · 10−11
females
1880s 2 3 0.005 0.076 4.0 · 10−6 1.0 · 10−5 2.2 · 10−10
1890s 2 3 0.007 0.098 1.6 · 10−6 2.2 · 10−5 3.1 · 10−11
1900s 2 3 0.009 0.138 1.6 · 10−6 5.8 · 10−6 9.3 · 10−11
1920s 2 3 0.019 0.172 1.1 · 10−6 8.3 · 10−6 1.6 · 10−11
males
1880s 3 4 0.017 0.333 2.2 · 10−5 8.9 · 10−8 7.5 · 10−10
1890s 3 4 0.026 0.224 2.6 · 10−5 3.7 · 10−6 2.1 · 10−9
1900s 3 4 0.032 0.173 2.9 · 10−5 2.0 · 10−5 8.0 · 10−10
1920s 3 4 0.043 0.225 2.3 · 10−5 1.1 · 10−5 9.6 · 10−11
females
1880s 3 5 0.005 0.070 9.7 · 10−5 5.7 · 10−6 2.0 · 10−10
1890s 3 5 0.008 0.375 2.1 · 10−5 1.4 · 10−9 8.2 · 10−10
1900s 3 5 0.009 0.147 3.4 · 10−5 1.4 · 10−5 1.5 · 10−10
1920s 3 5 0.014 0.180 3.2 · 10−5 1.9 · 10−5 1.3 · 10−11
Table 8: Model (18) applied to the lung cancer data for several fixed (n1, n2) .
Note the surprisingly strong influence of the choice of (n1, n2) on pˆi1 for
the males cohorts. No good fits were obtained for the females cohorts for
(n1, n2) = (3, 4) , but only for (n1, n2) = (3, 5) , which seems biologically
unreasonable. In all shown cases we set N0 = 109 and δ = 0 .
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ulation parameters into the multistage model. The fraction at risk, F ,
quantifies the proportion of susceptibles. And the fraction of deaths
due to the cancer among all deaths due to either cancer or related
causes, f , models the behavior of competing but related risks. The
observable hazard rate then becomes
h(t)× F
F + (1− F ) exp
(
(1/f)
∫ t
0
h(u) du
) , (19)
where h(t) is the hazard function of the multistage carcinogenesis model.
Similarly to the previous sections, we fit model (19) to the lung
cancer data from the males 1880s cohort using analytic graduation.
Table 9 gives the numerical results for a list of several fixed f . We can
see that completely different combinations (f, F ) can lead to equivalent
models in terms of goodness of fit. Nevertheless, the product f · Fˆ is
quite stable. Note that f · F corresponds to the proportion of the
population that will actually die from the cancer. This corresponds to
the individuals at high risk in our finite mixture models, measured for
example by piu = 1− pil in the γ-frailty model (15).
f Fˆ γˆ νˆ µˆ RSS
0.1 0.220 0.191 7.9 · 10−8 2.9 · 10−6 2.8 · 10−10
0.2 0.118 0.187 1.1 · 10−7 3.3 · 10−6 2.9 · 10−10
0.5 0.049 0.185 1.7 · 10−7 3.5 · 10−6 3.0 · 10−10
1.0 0.025 0.185 2.4 · 10−7 3.6 · 10−6 3.0 · 10−10
Table 9: Parameter estimates for model (19) for several fixed f . The re-
maining parameters were set to N0 = 1010 , δ = 0 , n = 2 .
The mixture models we presented in the previous sections did not
consider competing related risks. The corresponding fraction at risk
model is the one with f = 1 . Note that in such a model there still
are competing risk factors. But these factors are supposed to act in
a homogeneous manner on the whole population and therefore do not
alter the observable hazard. The deaths caused by such independent
factors correspond in fact to the censored individuals.
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Similarly to Morgenthaler et al. (2004), we can introduce related
competing risks into the γ-frailty model. We make the same simplify-
ing assumption of constant fraction of deaths due to cancer among all
deaths due to either cancer or competing related causes,
hpop(t)
hpop(t) + hrel(t)
= f ,
where hpop(t) is the population hazard function of model (15), and
hrel(t) the hazard function due to competing related risks. Then, the
observable hazard rate we fit to our data is
hobs(t) = hpop(t) · f . (20)
Table 10 gives the numerical results we get for several fixed f . We
find again the almost constant fraction that will actually die from the
cancer, which is in this model
f · (1− pˆil) ≈ 0.024 .
Note that only the product f ·pil is identifiable, but not the pair (f, pil) .
f pˆil γˆu νˆ µˆ RSS
0.1 0.781 0.192 2.5 · 10−7 2.8 · 10−6 2.8 · 10−10
0.2 0.883 0.189 2.5 · 10−7 3.0 · 10−6 2.9 · 10−10
0.5 0.952 0.190 2.4 · 10−7 2.8 · 10−6 3.0 · 10−10
1.0 0.976 0.192 2.4 · 10−7 2.4 · 10−6 3.1 · 10−10
Table 10: Parameter estimates for model (20) for several fixed f . The other
parameters were set to N0 = 1010 , δ = 0 , γl = 10−4 , n = 2 .
Discussion
The applications above show that many different models can fit cancer
incidence data equally well. We note, however, some common features
of the different models fitted to our data. For every two component
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mixture model we used, we got satisfactory results only when we al-
lowed for two clearly separated population subgroups with a low risk
group that runs a risk close to zero. This immune sub-group is esti-
mated to be the large majority of the population. For example in the
males 1880s cohort we estimate that less than 2.5% are at high cancer
risk. Also, the models incorporating the concept of a fraction at risk
lead to the same conclusion.
The γ-frailty and µ-frailty models are such that only the parame-
ters involved in promotion vary. This would suggest a process where
initiated cells are created in all individuals (and following the same
dynamics), but only in a small subgroup of the population promotion
happens. This is consistent with the fact that epigenetic stimuli are
necessary for the last step in malignant transformation, and such fac-
tors might be present just in a fraction of the population.
Another observation concerns the proportion of the high risk group
among all individuals. The sharp increase of maximal incidence from
the 1880s cohorts to the 1920s cohorts is reflected in the marked growth
of pˆiu .
The different models are in close agreement for the first three cohorts
and differ only in the 1920s cohort, where not enough data at high ages
is available. In general, the biological parameters are in good agreement
between the models.
5.2.3 Counting Process Framework
The estimates we used in the previous section were all based on stan-
dard least squares. Their derivation and their asymptotic properties
being a direct application of analytic graduation introduced in Section
1.3.4. A more recent and very elegant way to derive such asymptotic
properties uses the counting process framework described in Section
1.3.2. The data we have at hand can be seen as arising from a count-
ing process in discrete time, and we will use this theory to show how
to derive asymptotic results in our case. We will use the same nota-
tions as before. In particular, (Ri, Oi) denote the population at risk
and the observed failures at time point ti , and Ci = Ri − Ri+1 − Oi
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is the number of censorings at ti . Let S(t) be the survivor function
of a multistage carcinogenesis mixture model we consider, where the
parameters are suppressed in the notation. Then,
λl =
S(tl)− S(tl+1)
S(tl)
is the intensity at tl of the corresponding failure model in discrete time.
The counting process notation can be introduced in the following
way. Let Ti and Xi be failure time (i.e. time of first malignant tumor
cell) and censoring time for subject i , where (Ti) and (Xi) are supposed
to be independent sequences of i.i.d. random variables. We denote
{Yi(t), t ≥ 0} the individual’s at risk process,
Yi(t) = I(Ti ≥ t,Xi ≥ t) ,
and the process {Ni(t), t ≥ 0} counts the observed number of events
up to time t for individual i ,
Ni(t) = I(Ti ≤ t, Ti ≤ Xi) .
Note that if Ti = Xi , then we count the event as an observed failure.
Let n be the total number of subjects in the study, that is n = r0 . We
observe the aggregated processes
N(t) =
n∑
i=1
Ni(t) =
∑
tl≤t
Ol ,
Y(t) =
n∑
i=1
Yi(t) =
∑
tl≥t
(Ol + Cl) .
We write the history of the process
Ft = σ{Ni(u), Yi(u+), i = 1, . . . n, 0 ≤ u ≤ t} , t > 0 .
Then, we have
P( dNi(t) = 1 | Ft−) = Yi(t) dΛ(t) ,
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where the intensity process is Λ(t) given by the step function
Λ(t) =
∑
tl≤t
λl .
Note that this deterministic process does not depend on individual i
because the model does not include covariates.
Least Squares
In order to estimate the biological parameters, we minimize with re-
spect to ψ the sum of squared differences between observed and ex-
pected hazard. Using the above discrete time model, we must minimize
RSS(ψ) =
N∑
l=0
(
Ol
Rl∆tl
− λl
∆tl
)2
. (21)
Recall that λl = λl(ψ) , but we will not write this dependency explicitly
in order to get shorter expressions. The time points tl are equidistant
in our data set, ∆tl = tl+1 − tl = 5 (years) for all l . Therefore, we can
write
RSS(ψ) ∝
N∑
l=0
1
R2l
(
Ol −Rlλl
)2
.
This leads to the estimating equations
N∑
l=0
1
Rl
(
Ol −Rlλl
) ∂
∂ψ
λl = 0 . (22)
Using the counting process notation and J(t) = I(Y(t) > 0), equation
(22) is equivalent to
√
n
∫ τ
0
J(t)
Y(t)
(
∂
∂ψ
∆Λ(t)
)(
dN(t)− Y(t) dΛ(t)
)
= 0 ,
where τ > aN is an artificial finite end-point. In other words, we search
for a solution ψˆ of the system∫ τ
0
Kj(t, ψ) dM(t, ψ) = 0 , j = 1, . . . , g ,
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where
Kj(t, ψ) =
√
n
J(t)
Y(t)
∂
∂ψj
∆Λ(t) ,
and ψ = (ψ1, . . . , ψg) . Note that, with respect to Ft , the process
Kj(t, ψ) is predictable and
M(t, ψ) = N(t)−
∫ t
0
Y(u)dΛ(u)
is a square integrable zero mean martingale. Since ∂∂ψj∆Λ(t) is con-
tinuous, Kj(t, ψ) is bounded on the compact set [0, τ ] (tN < τ < ∞) .
This implies that
U(t, ψ) =
(∫ t
0
Kj(u, ψ) dM(u, ψ)
)
j=1,...,g
, 0 ≤ t ≤ τ ,
is a square integrable multivariate martingale.
We aim at applying Rebolledo’s theorem to the process U(τ, ψ) .
Therefore, we consider a sequence of experiments indexed by n , the to-
tal number of subjects, and introduce corresponding processes N (n) (t) ,
Y
(n)
 (t) , Λ(n)(t) , U (n)(t, ψ), etc. Recall that we assume the processes
for different individuals to be independent. Let  > 0 be given. We
define the process
U
(n)
j (τ, ψ) =
∫ τ
0
K
(n)
j (t, ψ) I(|K(n)j (t, ψ)| > ) dM (n)(t, ψ) .
According to Rebolledo’s theorem,
(i) 〈U (n)〉(τ, ψ) P−→ V as n→∞ , and
(ii) 〈U (n)j 〉(τ, ψ) P−→ 0 as n→∞ , j = 1, ..., g ,
together imply that
U (n)(τ, ψ) D−→ N (0, V ) ,
where V is a g×g positive semi-definite matrix. To check conditions (i)
and (ii) for our situation, we first calculate1 the predictable variation
1See Kalbfleisch and Prentice (2002) equation (5.34).
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processes of U (n)j (τ, ψ) ,
〈U (n)i , U (n)j 〉(τ, ψ) =
N∑
l=0
n
(
J(n)(tl)
Y
(n)
 (tl)
)2 (
∂
∂ψi
λl
)(
∂
∂ψj
λl
)
×Y (n) (tl)(1− λl)λl
=
N∑
l=0
n
J(n)(tl)
Y
(n)
 (tl)
(
∂
∂ψi
λl
)(
∂
∂ψj
λl
)
×(1− λl)λl ,
and the predictable variation process of U (n)j (τ, ψ) ,
〈U (n)j 〉(τ, ψ) =
N∑
l=0
n
J(n)(tl)
Y
(n)
 (tl)
(
∂
∂ψj
λl
)2
×I
(
|√n J
(n)(tl)
Y
(n)
 (tl)
∂
∂ψj
λl| > 
)
(1− λl)λl .
In the above expressions, the only random element is the at risk process
{Y (n) (tl) , l = 0, . . . , N} . From its definition it follows that
Y
(n)
 (tl) ∼ B(n, ql) ,
where ql = P(Yi(tl) = 1) = P(Ti ≥ tl, Xi ≥ tl) . According to the law
of large numbers
Y
(n)
 (tl)
n
P−→ ql , as n→∞ .
We assume that the censoring mechanism is such that ql > 0, ∀ l . This
restriction ensures that function g(x) = 1/x is continuous at ql , ∀ l .
Therefore also
n
Y
(n)
 (tl)
P−→ 1
ql
, as n→∞ ,
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and consequently
√
n
Y
(n)
 (tl)
P−→ 0 , as n→∞ .
This implies that
〈U (n)〉(τ, ψ) P−→ V ,
where V is the g × g matrix with elements
Vij =
N∑
l=0
1
ql
(
∂
∂ψi
λl
)(
∂
∂ψj
λl
)
(1− λl)λl .
It also follows that
〈U (n)j 〉(τ, ψ) P−→ 0 , as n→∞ .
Note that V is symmetric. It is also positive definite as shown by the
following argument. Let us define
J =

∂
∂ψ1
λ0 . . .
∂
∂ψg
λ0
...
...
∂
∂ψ1
λN . . .
∂
∂ψg
λN
 and A = diag{(√λl(1− λl)/ql)l } .
Then we have V = JTA2J and therefore for an arbitrary vector x ∈ Rg ,
xTV x = (AJx)T (AJx) ≥ 0 .
This shows that all conditions of Rebolledo’s theorem are satisfied,
and we can deduce that U (n)(τ, ψ) converges to a multivariate normal
distribution with mean zero and variance-covariance matrix V .
Our estimate ψˆ of the unknown biological parameters is defined via
the estimating equations
U (n)(τ, ψ) = 0 .
The asymptotic variance, V (ψ, q0, . . . , qN ) , of U (n)(τ, ψ) depends on
the unknown probabilities
ql = P(to be at risk at time point tl) .
108 CHAPTER 5. APPLICATION TO DATA
These values can be estimated by the observed proportions at risk,
qˆl =
Rl
R0
, l = 0, . . . , N .
From this we get the estimate
Vˆ = V (ψˆ, qˆ0, . . . , qˆN ) ,
which finally leads to
U (n)(τ, ψˆ) ∼˙ N (0, Vˆ ) .
One can use this result to obtain an asymptotic confidence region for
ψ . Note also that it is straightforward to generalize this argument to
the weighted least squares estimate.
Modified Minimum Chi-Square
In the analytic graduation literature the use of a modified minimum chi-
square approach instead of the estimating equations (21) is sometimes
advocated. The idea is to estimate the variance of the raw hazard
estimates, and to weight the sum of squares by the inverse of these
variances. By maximum likelihood theory one can get
V̂ar(λˆl) = V̂ar(
Ol
Rl∆tl
) =
Ol
(Rl∆tl)2
.
The term modified is used since one uses variance estimates; see Hoem
(1976) for details.
If we apply this idea to our discretized count data, we must minimize
R˜SS(ψ) =
N∑
l=0
(
Ol
Rl∆tl
− λl∆tl
)2
Ol/(Rl∆tl)2
.
Using the same arguments as before, we get the estimating equations
N∑
l=0
Rl
Ol
(
∂
∂ψ
λl
)
(Ol −Rlλl) = 0 .
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In terms of our counting processes, we get the score process
U˜ (n)(ψ, τ) =
∫ τ
0
Y
(n)
 (t)√
n∆N (n) (t)
(
∂
∂ψ
∆Λl(t)
)
dM (n) (t, ψ) ,
where M (n) (t, ψ) is the martingale defined previously. Note that we
have introduced the normalizing factor 1/
√
n . Now we get
〈U˜ (n)i , U˜ (n)j 〉(ψ, τ) =
N∑
l=0
Y
(n)
 (tl)
n
(
Y
(n)
 (tl)
O
(n)
l
)2 (
∂
∂ψi
λl
)(
∂
∂ψj
λl
)
×(1− λl)λl .
Convergence of this processes can be established noting that
O
(n)
l
Y
(n)
 (tl)
P−→ λl ,
Y
(n)
 (tl)
n
P−→ ql ,
as n→∞ . Finally, we get
〈U˜ (n)i , U˜ (n)j 〉(τ, ψ) P−→ V˜ = JT A˜2J ,
where J is the same matrix as in the least squares case and
A˜ = diag
{(√
ql(1− λl)/λl
)
l
}
.
Again, we can apply Rebolledo’s theorem to show convergence of the
score process U˜ (n)(τ, ψ) to a multivariate normal with covariance ma-
trix V˜ .
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5.3 Finite Mixtures and Colon Cancer Data
Colon cancer is among the most frequently studied cancer types, and
a number of genes involved in its pathogenesis have been identified.
Several mechanisms can lead to colon cancer. Nevertheless, the same
signalling pathways seem to be affected. In particular, a sequence of
discrete events appears to cause colon cancer, which means that a mul-
tistage process applies. See Luebeck and Moolgavkar (2005) for more
biological details and for a recent application of the multistage model
to colon cancer data. According to these authors, initiation is thought
to be the result of mutation in both copies of the adenomatous polypo-
sis coli (APC) gene, and therefore we assume n = 2 . One further rare
event is needed for promotion. Finally, the number of stem cells can be
estimated by the number of crypts in the colon, about 108 , multiplied
by the number of stem cells per crypt. Assuming ten stem cells per
crypt we therefore get N0 ≈ 109 .
In the previous section, we applied several finite mixture models to
lung cancer data. We can perform a similar analysis with the colon
cancer data given in Table 4. Recall the corresponding raw hazard
estimates shown in Figure 11. Note that for the 1920s cohort incidence
data is available only up to the age interval 70-74 years. This is not
enough data to observe the levelling-off of the hazard curve and its
decrease at high ages. It thus makes no sense to fit our mixture models
to this data set. The 1900s group also does not contain sufficient data to
give reliable estimates, but in some cases the group is useful to indicate
and confirm trends. We will, therefore, focus on the 1880s and the
1890s cohorts in the sequel.
Random Number of Mutations for Initiation
Let us start with model (18), which splits the population into a first
group needing n1 mutations for initiation and a second group with
n2 such mutations. In the case of colon cancer it is natural to set
n1 = 1 and n2 = 2 . The group having already inherited one mutation
in the APC gene suffers from a syndrome called familial adenomatous
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Cohort Males Females
pˆi1 γˆ νˆ[10−7] µˆ[10−8] pˆi1 γˆ νˆ[10−7] µˆ[10−8]
1880s 0.025 0.095 1.5 0.9 0.022 0.093 1.2 1.4
1890s 0.030 0.117 1.8 0.1 0.024 0.105 1.4 0.4
1900s 0.038 0.099 0.4 2.5 0.043 0.077 0.1 15.8
Table 11: Parameter estimates by least squares (via analytic graduation)
corresponding to the curves in Figure 21. The fixed parameters are N0 = 109 ,
δ = 0 , n1 = 1 , and n2 = 2 .
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Figure 21: Two component mixture model (18) fitted to the colon cancer
incidence data by least squares (via analytic graduation).
polyposis (FAP). These individuals usually develop multiple benign
polyps in the colon, which then give rise to cancers later on in life.
We first determine the least squares estimates using analytic gradu-
ation. The numeric results are given in Table 11, and the corresponding
hazard curves are illustrated in Figure 21. The model fits the data from
the 1880s cohorts reasonably well. The estimated models for the 1890s
cohorts, however, are less satisfactory. The very narrow peak at old
ages of the observed hazard dominates the estimates. The model is not
able to explain both the slight onset of cases between the ages fifty to
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Cohort Males Females
pˆi1 γˆ νˆ[10−7] µˆ[10−8] pˆi1 γˆ νˆ[10−7] µˆ[10−8]
1880s 0.026 0.085 1.3 1.9 0.023 0.082 2.5 1.3
1890s 0.033 0.095 0.6 2.0 0.028 0.084 0.9 2.9
Table 12: Parameter estimates obtained via modified minimum chi-square
graduation. The fixed parameters are N0 = 109 , δ = 0 , n1 = 1 , and n2 = 2 .
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Figure 22: Two component mixture model (18) fitted to the colon cancer
incidence data by modified minimum chi-square graduation.
eighty and the sharp peak between ages eighty and a hundred years.
Since we fit by least squares, the estimate tries to avoid a large devi-
ation at the last data points and accepts in turn many small errors at
the beginning where the observed incidence is low. But the accuracy
of the raw hazard estimate at 100-105 years is questionable, while we
have more confidence in the first few data points. Note that the esti-
mates are quite sensitive to the starting values chosen. In many cases
the optimization scheme converges to local maxima with unacceptably
poor fit. Finally, as stated above, the 1900s cohort does not contain
enough information to yield trustworthy estimates. We will, therefore,
carry on with only the 1880s and the 1890s cohort.
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Figure 23: Projections of an asymptotic 95% confidence region for param-
eter ψ .
The above considerations suggest to downweight the influence of
the raw hazard estimates at high ages, for example by estimating ψ by
the modified minimum chi-square approach described previously. This
means ψˆ is the argument that minimizes
Q(ψ) = (λˆ− h(t∗;ψ))TM(λˆ− h(t∗;ψ)) ,
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where M = diag{(Ol/(Rl∆tl)2)−1 ; l = 0, . . . , N} . The estimates
we obtain now are given in Table 12 and Figure 22. We see that the
estimates can explain the raw hazard curves very accurately up to about
age eighty-five. The observed peaks at very old ages are, however,
somewhat smoothed. Figure 23 gives the confidence region for the
(transformed) parameter ψ . The proportion of the high risk group ,
pi1 , is estimated to lie within the range from 1.4% to 4.7% . The net
growth rate, γ , is thought to belong to the interval [0.079, 0.091] , which
surprisingly contains only values smaller than 0.1 . But we see also
that the two mutation rates, ν and µ , virtually vary from 0 to ∞ .
These two parameters compete, and even though theoretically they are
identifiable, we can in practice estimate only one of them, conditionally
on the value of the other.
Random Growth Advantage
We will also fit model (15) to the colon cancer data. This model con-
siders γ as a random variable with two states, γl and γu . We directly
apply both least squares and modified minimum chi-square graduation.
The results are given in Tables 13, 14 and Figure 24. Concerning the
fits, the same remarks as above apply: the least squares estimates pay
too much attention to the peak of the observed hazard, while the min-
imum chi-square estimates capture the onset of the different incidence
curves better. The estimated parameters νˆLS and µˆLS do not seem
biologically reasonable. But the corresponding estimates obtained by
minimum chi-square graduation are within sensible limits. Neverthe-
less, when we determine confidence regions for the estimates (based on
the chi-square approach), we still get huge confidence regions for the
mutation rates.
Discussion
Finally, we will briefly compare our results with the initially mentioned
papers by Luebeck and Moolgavkar (2002, 2005). These authors apply
the multistage model to incidence data from colorectal cancer. Their
data comes from US registries and covers the years from 1973 to 1996.
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Cohort Males Females
pˆil γˆu νˆ[10
−4] µˆ pˆil γˆu νˆ[10−4] µˆ
1880s 0.984 0.114 25 2.9 · 10−12 0.987 0.118 9.7 1.8 · 10−11
1890s 0.974 0.125 0.2 2.5 · 10−8 0.982 0.121 23 2.3 · 10−12
Table 13: Parameter estimates for the γ-frailty model applied to the colon
cancer data obtained by least squares. The fixed parameters are N0 = 109 ,
δ = 0 , n = 2 , and γl = 0.01 .
Cohort Males Females
pˆil γˆu νˆ[10−5] µˆ[10−8] pˆil γˆu νˆ[10−5] µˆ[10−8]
1880s 0.986 0.113 4.0 1.3 0.989 0.113 3.6 1.7
1890s 0.976 0.118 3.3 1.3 0.984 0.114 4.8 0.9
Table 14: Parameter estimates for the γ-frailty model applied to the colon
cancer data obtained by modified minimum chi-square graduation. The fixed
parameters are N0 = 109 , δ = 0 , n = 2 , and γl = 0.01 .
Their model aims at the elucidation of temporal trends. Therefore,
they work with the age dependent hazard curve
hij(t) = bicjh(t) ,
where bi accounts for birth year, cj for calendar year, and h(t) is the
exact hazard curve of the multistage clonal expansion model. The in-
dices for birth year and calender year i, j and the age t are related by
i = j − t . The parameters are then estimated by maximum likelihood,
assuming that the counts in each cell of the given contingency table
follow a Poisson distribution with mean (person years)ij · hij(t) . The
model with largest likelihood postulates two rate limiting steps for ini-
tiation and one further rate limiting step for malignant transformation.
They estimate a net proliferation rate of initiated cells of 0.13 for fe-
males and 0.15 for males. The estimated mutation rates are of the order
of 10−6 for the initiating mutations. The uncertainty for the malignant
transformation is much higher, with values in the range from 10−9 to
10−6 that might all be reasonable under certain conditions. Concerning
temporal trends, calendar year was most important with a peak around
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Figure 24: Estimated hazard curves of the γ-frailty model applied to the
colon cancer data. The top panels were obtained by least squares graduation,
the bottom panels by minimum chi-square graduation.
1985. Luebeck and Moolgavkar state that improved screening can be a
possible explanation.
These results are consistent with our estimates from the γ-frailty
model obtained by minimum chi-square graduation, reported in Table
14. Our γˆu is in good agreement with their values. The mutation rates
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must be compared with care, since we assume N0 = 109 , while Luebeck
and Moolgavkar work with N0 = 108 . But the two models seem to be
in reasonable accordance. However, the scopes of the works are quite
different, which explains the different modeling strategies.
5.4 Continuous Mixture Models
Up to now we have considered finite mixture models to describe the ef-
fect of heterogeneity of the population on the observed hazard curves.
This implicitly assumed clearly separated population subgroups. But
what would happen, if differences between individuals were less marked?
We can imagine more subtle frailty effects. Some risk factors might af-
fect a biological parameter in such a way that it varies continuously
over the population. Therefore, it is natural to consider also continu-
ous mixture models.
In Section 3.4 we introduced continuous mixtures of the multistage
model. In particular, we proposed to model the net growth advantage
γ by a beta distribution with support [γl, γu] . We will pursue this
approach here. Recall the population hazard function,
h(t) =
∫
h(t|γ)S(t|γ)
S(t)
f(γ) dγ , (23)
where the density of γ is
f(γ) =
1
B(a, b) · (γu − γl)a+b−1 (γ − γl)
a−1(γu − γ)b−1 .
In order to understand the effect of such a γ−frailty on h(t) , we calcu-
late h(t) for some choices of (a, b) for the fixed support
[γl, γu] = [0.02, 0.2] .
Figure 25 shows the resulting population hazard curves. We have
seen in Chapter 3, that monotonicity of h(t) depends on the range of
possible γ-values. Figure 25 illustrates another important effect: h(t)
has a peak if there is enough separation of the population into high
risk and low risk individuals. The value of h(t) at the local maximum
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Figure 25: Population hazard curve (23) for several shape parameters of
f(γ) . Top row: black line, a = b = 2 ; red line, a = 2 , b = 6 , green line,
a = b = 1 . Middle row: black line, a = 0.8 b = 2 ; red line, a = 2 b = 0.8 .
Bottom row: black line, a = b = 0.8 ; red line, a = 0.4 b = 0.8 ; green line,
a = 0.8 b = 0.4 . The biological parameters are N0 = 1010 , δ = 0 , ν =
3.2 · 10−7 , µ = 10−5 and n = 2 .
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depends on the proportion of high risk individuals. Comparing these
hazard curves to the observed hazard from lung and colon cancer, we
realize that the shown models would predict too large incidences. Can-
cer is a rare disease, and the observed hazards count at most some
hundred cases per 105 . Figure 25 shows that realistic models could be
obtained only with bathtub shaped densities f(γ) that put most of the
probability mass to the lower end of [γl, γu] . But such densities closely
resemble two component mixtures as those studied in the previous sec-
tion. This means that in our application, we do not gain further insight
by working with the more complex continuous mixture models.
Discussion
The above results can be interpreted in biological terms. We found
that the data suggests population heterogeneity in form of two clearly
separated subgroups, rather than in form of continuous variation over
some range. In order to understand this, we must keep in mind that
we look at the end-point, namely cancer, of a complicated process. But
biological systems are usually buffered. Small changes in the environ-
ment have no significant effect, and abrupt changes in a system may
occur only after passing over some threshold value. Our population in-
cidence data gives a global picture of the disease. There is not enough
information in such data to investigate more subtle differences between
individuals. But the frailty effect observed in the presented data sets
can be explained by the combination of a large immune group with a
small high-risk group.
Note that our conclusion is consistent with the results reported by
the various approaches summarized in Chapter 3. In Morgenthaler
et al. (2004) heterogeneity is modelled via the fraction at risk, F , and
the fraction of deaths due to cancer, f . We have seen in Section 5.2.2
that f ·F roughly corresponds to our proportion of high risk individuals
(for example piu in the case of the γ-frailty model). Using lung cancer
incidence data one finds f ·F ≈ 2% . In Aalen and Tretli (1999) and in
Moger et al. (2004) the frailty model hind(t|Z) = Z ·h0(t) is used, where
Z is modelled with the compound Poisson distribution. This explicitly
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allows for the possibility of immune individuals. These authors apply
their model to Scandinavian testicular cancer incidence data. They
report a proportion of susceptibles significantly lower than 0.5% for all
birth cohorts before the 1950s.
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CHAPTER 6
Heterogeneity
Up to now, we have discussed various ways to introduce frailty into the
multistage carcinogenesis model. Our interest focused on the mathe-
matical and statistical problems. In this final chapter, we will consider
population heterogeneity itself, that is, the question of how frailty dif-
ferences are created. Some examples of questions that arise with respect
to heterogeneity are:
• Sources: which are the main factors that cause variation in cancer
susceptibility? Cancer is a genetic disease, but it is also strongly
related to exposure to risk factors. Which genes are involved?
Which substances are carcinogenic at which doses and exposure
patterns? How important are gene-environment interactions? Al-
though a lot is known about cancer, these questions are still driv-
ing forces of a lot of biomedical research.
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• Biological mechanisms: for known genes, which specific mecha-
nisms at molecular, cellular or tissue level are affected, and how
do these mechanisms result in heterogeneity?
• Types of heterogeneity: discrete groups or continuous traits, life-
long constant predisposition or time dependent relative risk, re-
versible or irreversible effects - which patterns of heterogeneity
are observed, which can be observed?
• Assessment: what type of data is needed to make inference about
heterogeneity? What can we infer from currently available data
and how should future experiments be designed to assess hetero-
geneity?
All the above points pose challenges for statistical and biological mod-
eling. We will briefly discuss some of the issues. However, we do by
no means claim completeness, since a thorough treatment would be
worthy of a thesis on its own. The selection of topics is somewhat
arbitrary. Our aim is to illustrate further uses of statistics in carcino-
genesis research. In particular, we attempt to embed the multistage
model into a wider view of cancer biology, since up to now our dis-
cussion of multistage carcinogenesis has focused on the mathematical
aspects.
6.1 Early Onset Cancer
The simplest possible situation are cancers caused by a single gene. We
have already mentioned the prototype of such a cancer in Chapter 3:
Retinoblastoma (RB), a cancer of the eye. RB is caused by a tumor
suppressor gene (recessive) called RB1, which was the first gene to be
linked to a familial cancer. The cancer is observed in a hereditary and
in a sporadic form. In the former case, individuals inherit a mutated
copy of the RB1 gene, and a single hit is enough to cause cancer. In the
latter case, two somatic mutations are necessary. Mutations in RB1 are
highly penetrant; children who inherit a mutated copy develop RB with
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about 90% probability. This means that although RB1 mutations are
physiologically recessive alleles, the syndrome is inherited dominantly.
It is enough to inherit one mutated copy to be at risk. The hereditary
form therefore affects mainly small children and causes a peak in the
observed hazard curve at young ages. As mentioned earlier, a natural
model to describe such a cancer is a two component mixture,
S(t) = pi1S1(t) + pi2S2(t) , (24)
where S1(t) , S2(t) are the survivor functions of a carcinogenesis model
with one, and with two genetic hits respectively. The estimate pˆi1 cor-
responds to the proportion of susceptibles to familial RB.
Simple Mendelian Models
Severe early onset diseases caused by a single gene generally show
Mendelian inheritance. One can link the estimated proportion of high-
risk individuals with methods from population genetics to make for
instance inference on distributions of alleles. We will consider a bial-
lelic locus, such that w denotes the wild-type allele and v the mutant
allele. The genotype frequencies pww , pwv , pvv can be expressed in
terms of the allele frequencies pw , pv . Under Hardy-Weinberg con-
ditions we have pww = p2w , pwv = 2pwpv , pvv = p2v . Mutations can
perturb this equilibrium. For example in the case of a recessive muta-
tion deleterious for reproductive fitness, only the genotypes ww and wv
contribute to the next generation. For a dominant deleterious mutation
solely the genotype ww is capable to reproduce. Let µ denote the rate
per generation of an irreversible germ line mutation w → v . Then, the
genotype and allele frequencies will reach an equilibrium under certain
conditions:
• dominant deleterious mutation: since only the individuals with
genotype ww reproduce, all alleles v in the population are due to
new mutations. The proportion of allele v must thus be equal to
the mutation rate, pv = µ . Since mutation rates are usually very
small, we have pwv ≈ 2µ and pvv ≈ 0 .
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• recessive deleterious mutations: homozygous variant individuals,
vv , do not reproduce. An equilibrium is reached if they are re-
placed by new mutations. This leads to µ = pvv = p2v .
We can make similar considerations for RB and link them with the
mixture model (24). But the expressions for the deleterious cases can
not be applied directly, since RB is fortunately not fatal. In order
to infer some information on µ , we write the genotype and the allele
frequencies as a function of time, which we will count in generations.
This means, we will write for generation k
pww(k) = pw(k)2 , pwv(k) = 2pw(k)pv(k) , pvv(k) = pv(k)2 ,
and so on. We must also introduce ξ , the survival probability given
one develops RB. Finally, let ρ(v) denote the penetrance of the allele
v , that is, the probability that an individual that carries the allele v
will actually develop the disease. Since pi1 measures the proportion
of familial RB, we can link this parameter to the frequencies of the
genotypes wv and vv ,
pi1 ≈ [pwv(k) + pvv(k)]ρ(v) . (25)
We will make the simplifying assumption that individuals with geno-
type ww will not develop RB before transmitting their alleles to the
next generation. Only alleles contributed from the genotypes wv and
vv are removed with a certain probability. Then, we can derive the
proportions of alleles, that reach reproduction,
p˜w(k) = pww(k) +
1
2
{pwv(k)[1− ρ(v)] + pwv(k)ρ(v)ξ}
= pww(k) +
1
2
pwv(k)[1− ρ(v)(1− ξ)] ,
p˜v(k) = pvv(k)[1− ρ(v)] + pvv(k)ρ(v)ξ + 12pwv(k)[1− ρ(v)(1− ξ)]
= [1− ρ(v)(1− ξ)] · [pvv(k) + 12pwv(k)] .
6.1. EARLY ONSET CANCER 127
Note that r(t) = p˜w(k) + p˜v(k) < 1 . For the passage to the next
generation, we must take the mutation µ : w → v into account. The
alleles, that will actually give rise to generation k + 1 , will be present
in the proportions
˜˜pw(k) = p˜w(k)(1− µ) ,
˜˜pv(k) = p˜v(k) + p˜w(k)µ .
In an infinite-alleles model, this leads to the genotype frequencies in
generation k + 1 ,
pww(k + 1) =
( ˜˜pw(k)
r(k)
)2
,
pwv(k + 1) = 2
˜˜pw(k)
r(k)
˜˜pv(k)
r(k)
,
pvv(k + 1) =
( ˜˜pv(k)
r(k)
)2
.
The normalizing factor is still the same since ˜˜pw(k) + ˜˜pv(k) = r(k) .
If we assume that the population has reached an equilibrium state, we
can derive an expression for µ by solving the equation
˜˜pw(∞)
r(∞) = pw(∞) ,
which leads to
µ =
ρ(v)(1− ξ)pw(∞)pv(∞)
1− ρ(v)(1− ξ)pv(k) . (26)
Using the information available at the website of the National Cancer
Institute1, we can get a numerical example. Namely, we get for RB the
values for
• penetrance: ρ(RB1v) ≈ 0.9 ;
1http://cancernet.nci.nih.gov/cancertopics/types/retinoblastoma/
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• survival: ξ ≈ 0.93 ;
• prevalence: the cumulative hazard among children up to about
five years is in the order of a few tens of cases per million, so
we get roughly the order of magnitude of the high risk group,
pˆi1 ≈ 2 · 10−5 .
We first plug these values into equation (25) to get an estimate of
pv(∞) . This value can then be used together with equation (26), which
finally leads to
µ ≈ 7 · 10−7 .
This value, a mutation rate per generation, is rather low compared
to other estimates that can be found in the literature. It is not un-
consistent, though, and can serve as an illustration of the use of this
type of modeling.
Evolutionary Perspective
We can say that in the RB example heterogeneity is caused by a clearly
identified gene. Therefore, the population is split into two subgroups,
and in a mechanistic carcinogenesis model heterogeneity manifests it-
self through precisely determined parameters. This is an ideal but rare
situation. According to Nunney (2003), it is likely that RB is the only
human cancer that is regulated by a single gene. This author gives an
evolutionary interpretation of this observation. Natural selection favors
the suppression of pre-reproductive cancers. But the response to such
selection is presumably tissue specific. The retina is a relatively small
tissue, and proliferation is basically limited to the growth period of the
individual. Control and repair mechanisms are expected to be more
complex for cells that divide more often, at higher frequency, or that
are more exposed to risk factors. One can also assume that larger ani-
mals with late reproductive age show more elaborate tumor suppressor
mechanisms than smaller ones. For example, one can speculate that
the number of tumor suppressor genes found in humans is larger than
the number of such genes found in mice. This leads to the important
6.1. EARLY ONSET CANCER 129
question whether conclusions from animal models can be applied to
human carcinogenesis or not.
We will illustrate the necessity for more than one tumor suppres-
sor gene as tissue size increases using a very simple model based on
branching processes. A detailed discussion of such techniques can be
found in Kimmel and Axelrod (2002). We will model an expanding tis-
sue by geometric growth. That is, we consider one normal cell at time
zero, N0 = 1 . This cell and all its descendants are assumed to divide
simultaneously at every time step. Thus there are two cells at time 1 ,
four cells at time 2 , and so on. In other words, the total number of
cells at time k is Nk = 2k .
We will start with the simplest case of a single dominant mutation
that leads to cancer. This would correspond to a (hypothetical) syn-
drome caused by one oncogene. We assume that during cell division a
daughter cell gets the mutation with rate α , and both daughter cells
act independently. Let M (0)k , M
(1)
k count the number of cells without
mutation (type 0 cells), and the number of cells with a mutation (type
1 cells) at time k . We assume that (M (0)0 , M
(1)
0 ) = (1, 0) . Then, we
get the transitions given in the table below.
(M (0)0 ,M
(1)
0 ) (M
(0)
1 ,M
(1)
1 ) with probability
(1,0) (2,0) (1− α)2
(1,1) 2α(1− α)
(0,2) α2
This means we model the expanding tissue by a multistate Galton-
Watson process. The mutation is assumed to be irreversible. Therefore,
a type 1 cell gives always rise to two type 1 cells at cell division. We
can calculate the probability of no mutated cells at time k ,
P
(
M
(1)
k = 0
)
= P
(
M
(1)
k = 0|M (1)k−1 = 0
)
P
(
M
(1)
k−1 = 0
)
= . . .
= (1− α)2(2k−1) .
Similarly, it is easy to derive the expected number of type 1 cells at
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time k ,
E
(
M
(1)
k
)
= E
(
2M (1)k−1 + 2α(Nk−1 −M (1)k−1)
)
= . . .
= 2k[1− (1− α)k] .
When the mutation is recessive (as is the case for tumor suppressor
genes), we must introduce the cells that carry two mutations. We will
say that these cells are of type 2, and count them by the process M (2)k .
Let us note α1 the rate of the first mutation and α2 the rate of the
second one, then we get the transitions given below.
(M (0)0 ,M
(1)
0 ,M
(2)
0 ) (M
(0)
1 ,M
(1)
1 ,M
(2)
1 ) with probability
(1,0,0) (2,0,0) (1− α1)2
(1,1,0) 2α1(1− α1)
(0,2,0) α21
(0,1,0) (0,2,0) (1− α2)2
(0,1,1) 2α2(1− α2)
(0,0,2) α22
(0,0,1) (0,0,2) 1
In this case, it is useful to introduce the probability generating functions
gi(s0, s1, s2; k) , i = 0, 1, 2 , of the vector (M
(0)
k ,M
(1)
k ,M
(2)
k ) , where
gi(s; k) is the function we get when the process starts from a single
type i cell at time k = 0 . Using the above table, one can derive the
recursions
g0(s; k + 1) = [(1− α1)g0(s; k) + α1g1(s; k)]2 ,
g1(s; k + 1) = [(1− α2)g1(s; k) + α2g2(s; k)]2 ,
g2(s; k + 1) = g2(s; k)2 ,
with initial condition gi(s; 0) = si , i = 0, 1, 2 . We will note pi(k) =
gi(1, 1, 0; k) the probability of no type 2 cell at time k . The recursive
equations imply that p2(k) = 0 , p1(k) = (1− α2)2(2k−1) , and
p0(k + 1) = [(1− α1)p0(k) + α1p1(k)]2 , p0(0) = 1 .
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The expected number of type 2 cells can be derived using
E
(
M
(2)
k
∣∣ (M (0)0 ,M (1)0 ,M (2)0 ) = (1, 0, 0)) = ∂∂s2 g0(s; k)
∣∣∣∣
s0=s1=s2=1
.
In order to estimate the numbers of cell divisions necessary to build a
tissue under such a model, Table 15 summarizes rough estimates of the
size of some organisms or tissues that can be found in the literature.
The probabilities of no mutated cells as a function of tissue size for
both the dominant and the recessive case are shown in Figure 26. It
becomes clear that only for very small tissues, such as the retina, a
single tumor suppressor gene may be enough to prevent the occurrence
of cancer before reproductive age.
Species/Tissue Estimated Size Nb. of Doublings
(Nb. of cells C) (k = log2 C)
C. elegans2 103 9.9
D. melanogaster2 5·106 22.3
Retina3 4·106 21.9
Colon (dividing cells)4 1010 33.2
Human body (adult)5 5·1013 45.5
Table 15: Estimated numbers of cells for some organisms or tissues.
6.2 Association Studies
The study of early onset cancers shows that almost all cancers are
caused by more than one gene. When we try to get an overview of
the genes that are known to be related to cancer, we realize that the
list of such genes is actually very long. A review of currently known
2See Nunney (1993).
3See Hethcote and Knudson (1978).
4See Michor et al. (2004).
5See Tomlinson et al. (2002).
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Figure 26: Probability of no state 1 cell (dominant case), and of no state 2
cell (recessive case). The vertical lines indicate the estimated number of cells
in C. elegans (dotted line), in the retina (dashed line), and in the colon.
cancer genes can be found in Futreal et al. (2004). These authors give
a list of 291 genes that have been reported to be causally implicated
in oncogenesis. This means that up to now more than 1% of the total
human genome has been linked to cancer. Such cancer genes are mainly
related to the regulation of cell proliferation, cell differentiation, cell
death, and DNA repair. But there seems also to be a strong genetic
control of the amount of hormones a tissue is exposed to. So in some
cases such as breast cancer susceptibility genes could also be involved
in hormone pathways (see Kolonel et al. (2004)).
The identification of susceptibility genes traditionally uses family
studies and population based association studies (case-control studies).
Futreal et al. state that up to now most associations reported in the lit-
erature have not been confirmed in subsequent surveys. They mention
false positives and publication bias as possible explanations. Popula-
tion heterogeneity can be another reason for a lack of reproducibility
of reported results. According to Cardon and Palmer (2003), allele fre-
quencies vary quite markedly within and between populations - often
irrespective of disease status. Furthermore, cancer susceptibility alle-
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les are generally very rare. This shows that these alleles are of recent
origin. This is confirmed by the observation, that there are many dif-
ferent susceptibility genes, and that those genes have different effects in
different tissues. Moreover, there seems to be a species barrier: many
cancer genes affect different organs when mutated in mice than when
mutated in humans (see Vogelstein and Kinzler (2004)).
In the study of cancer causing genes not only mutations, but also
regulation is of importance. Changes in phenotype - including cancer
- must not necessarily be due to changes in genotype. They can also
be a consequence of epigenetic regulation. For example, tumor sup-
pressor genes might be epigenetically silenced. Epigenetic alterations
presumably reflect exposure to risk factors. This shows that it is not
enough to identify lists of genes that are related to carcinogenesis. The
understanding of gene-gene and gene-environment interactions is the
real challenge, and population heterogeneity with respect to cancer
risk seems to stem from the combination of polygenic interactions with
specific environmental settings.
6.3 Gene-Gene Interactions
The ability of one or more genes to alter the action of another gene
is called epistasis. A simple example of epistasis is the albino gene,
which can mask the effect of the gene that determines hair color. The
discovery and elucidation of gene-gene interactions is a difficult task
from both the biological and the statistical point of view. A review
of mathematical methods used to investigate multi-locus traits can be
found in Hoh and Ott (2003).
A natural idea is to try to extend single locus methods to the multi-
locus case. One such approach is the use of sums of single-marker
statistics. For example, one can calculate a measure of association
(as the χ2 statistics) using contingency tables for every marker. This
would lead to a sequence t1, . . . , tn . An ad hoc procedure to identify
groups of interacting genes consists in combining the order statistics,
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t(1), . . . , t(n) , into sums
sk =
n∑
i=n−k+1
t(i) .
For fixed k one can assess p-values by resampling methods. This can be
repeated for several k , and one can select subsets of markers that seem
to be most important. Such methods must find a trade off between
selecting enough genes to hopefully capture those related to the disease
and between selecting to many markers and thereby accepting a high
proportion of false positives. But in any case, such procedures can
only propose candidates for further investigation. Whether interaction
is present and how it could work must then be studied using more
sophisticated modeling. See Hoh et al. (2000) for more details.
To directly investigate interactions among genes, we should clearly
prefer methods that make a joint analysis of all genes. In principle,
logistic regression can be used. However, the number of possible inter-
actions grows exponentially with the number of makers. Therefore, the
number of parameters to be estimated in a full model becomes quickly
too large. In practice, often only pairwise interactions can be explained.
The difficulty of parametric models to handle high-order interac-
tions suggests the use of model free methods. Given the usually very
large number of candidate genes, it seems appealing to use statistical
learning theory to recognize patterns of genes related to disease out-
come. We will consider one recently proposed such method in some
more detail.
Polymorphism Interaction Analysis
In Goodman et al. (2006) an algorithm called Polymorphism Inter-
action Analysis (PIA) was proposed. It aims at the identification of
interactions among Single Nucleotide Polymorphisms (SNPs) that re-
sult in an increase in colon cancer risk. PIA is a slight generalization of
a method called Multifactor-Dimensionality Reduction (MDR), which
was first proposed in Ritchie et al. (2001). MDR was designed to detect
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high-order gene-gene (and gene-environment) interactions using geno-
typed case-control data. That is a set of cancer patients and a set of
matched controls are chosen. Then, the genotypes at N selected SNP-
sites are determined. The SNPs are defined a priori and supposed to
be relevant for the disease.
The MDR algorithm is a simple classification scheme for which
the mis-classification and the prediction errors are estimated via cross-
validation (CV). A subset ofK SNPs is selected, then the 3K genotypes
are classified as high risk and low risk according to whether
nb. of cases (genotype)
nb. of controls (genotype)
≥ T
or not. The threshold T is fixed in advance; usually T = 1 . For a
given order of interactions, that means for a given number K , MDR
chooses among the
(
N
K
)
combinations the set of SNPs with the lowest
CV prediction error. PIA is a generalization in the sense that it allows
for two different cost functions to judge the quality of the model. The
first is the Gini index (see for example Hastie et al. (2001)). The second
one, called %-wrong, is simply the misclassification error of the chosen
model when applied again to the whole data (as opposed to the data
split into training and testing sets).
In the article MDR was proposed, the method was applied to spo-
radic breast cancer data. It was claimed that MDR had identified a
new four locus interaction among a list of 10 candidate SNPs. The CV
prediction error of the selected model was 46.7% . In Xu et al. (2005)
MDR was applied to prostate cancer. Their analysis included 57 SNPs.
Again a four locus model was reported to predict cancer risk best. In
this case, the estimated prediction error was 37.7% .
The researchers that proposed PIA used colon cancer data. They
explored all combinations up to fourth order among 94 SNPs. The
reported %-wrong scores of the best first, second, third, and fourth or-
der models were 43.7% , 40.0% , 35.3% , and 31.7% . The researchers
admitted in their discussion the possibility, that a SNP combination
could have been selected due to chance as a consequence of the large
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number of sites considered. But they did not really account for multi-
plicity in their analysis. Consequently, these authors see their method
as an identification procedure, which can narrow down the list of SNPs
that seem to be able to explain cancer risk. They do not claim PIA to
be powerful enough to reliably find gene-gene interactions, and do not
advice to apply PIA as a stand alone method.
From the statistical point of view, the above described results are
not satisfactory at all. The prediction errors are extremely large, and
can actually be explained solely by random variation. We will illustrate
this by means of a simulation. For 200 cases and 200 controls, we
randomly generate genotypes. We sample for every SNP independently
from the same multinomial distribution,
M (1 ; p2w , 2pw(1− pw) , (1− pw)2) .
This means we assume a Hardy-Weinberg equilibrium for every locus
with frequency of the wild-type allele pw . We then apply the MDR/PIA
classification for several numbers of candidate SNPs. Figure 27 shows
the CV classification and prediction errors for second and third order
interactions. We see that the prediction and classification errors drop
markedly as the number of candidate SNPs or the order of interactions
increase. The values obtained by our simulation are comparable to
the results of the above described studies. So in our example, we find
SNP combinations that discriminate cases and controls equally well
as the interactions reported in the literature. Nevertheless, there is
no relationship between disease status and genotypes in our simulated
datasets.
Besides the problem of multiplicity, our simulation brings up an-
other question: which part of cancer incidence can be explained by
genetic predisposition? In other terms: how much is environmental,
and how much is genetic? It is an appealing idea to relate cancers
that cannot be explained by single genes and Mendelian patterns to
more complicated gene-gene interactions. But the approach of just
listing enough genes and then comparing genotype frequencies in cases
and controls is too simplistic. Even when methods such as MDR/PIA
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Figure 27: Boxplots of CV classification and prediction errors from 100 sim-
ulations for several numbers of candidate SNPs. The frequency of the wild-
type was pw = 0.7 , and we split the data into 10 parts for cross-validation.
These values were chosen in order to mimic the conditions of the studies,
where MDR/PIA were proposed. The horizontal grey lines give the %-wrong
scores of the best models found in Xu et al. (2005) using PIA for the cor-
responding order of interactions. We get models with comparable CV errors
from about 50 SNPs on, though the above mentioned authors included 94
SNPs in their analysis.
would account properly for the multiplicity problem, they must fail in
situations, where exposure to carcinogens and lifestyle are the main
risk factors. If cancer is caused predominantly by sporadic mutations,
and if the impact of genetic predisposition is small, then such interac-
tion analysis will not give meaningful results. Note that environmental
agents could be considered in MDR/PIA. The inventors of MDR state
that not only SNPs, but any discrete variable can be integrated in their
analysis. One simply has to define exposure groups. The environmental
factors are then treated just as the SNPs in the analysis.
The issue of genes and environment is crucial, and we will discuss
the problem of how to disentangle genetic and environmental causes of
cancer in the next section.
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6.4 Familial Risk
The classical approach to estimate the heritable contribution to cancer
uses family and especially twin data. For example, one can determine
standardized incidence ratios (SIR) for monozygotic (MZ) and dizy-
gotic (DZ) twins. SIR means the observed incidence rate for a given
group is determined and divided by the expected incidence rate for
the general population. Since MZ twins share twice as much genetic
information as DZ twins, a purely additive genetic effect should lead
to a ratio SIRMZ/SIRDZ of about two. A ratio larger than two, how-
ever, would suggest interactions: either non-additive genetic effects or
gene-environment interactions. The same considerations hold for the
comparison of full siblings with half siblings. An application of this
idea using Swedish twin data can be found in Ahlbom et al. (1997).
Besides the computation of relative risks, methods from quantitative
genetics can be used to assess genetic and environmental contributions
to cancer. Since one deals with a dichotomous outcome, generalizations
of the methods for continuous variables must be used. The liability-
threshold model assumes that cancer is determined by a standard nor-
mal random variable D , such that a person gets affected if D exceeds
some unknown threshold. In a structural model the liability D is de-
composed into several sources. For example in Czene et al. (2002) the
model
D = G+ S + F + E (27)
is used, where G accounts for genetic effects, S for shared environmen-
tal effects, F for shared childhood environment effects, and E for un-
shared environmental effects. All variables are assumed to be centered
and independent. Since D is standard normal, one gets the variance
decomposition
σ2G + σ
2
S + σ
2
F + σ
2
E = 1 .
These variances can be estimated using the known correlation structure
among family members. This means one assumes
• for two spouses: Cov(D1, D2) = σ2S ;
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• for full sibs: Cov(D1, D2) = 0.5σ2G + σ2S + σ2F ;
• for half sibs: Cov(D1, D2) = 0.25σ2G + σ2S + σ2F .
Equating this to the corresponding estimated tetrachoric correlations,
one gets a system of linear equations for the unknown variances. The
tetrachoric correlation estimated from a 2 × 2 contingency table for
a liability-threshold model is an estimate of the correlation between
the underlying continuous variables D1, D2 . For more details see for
example Sham (1998).
According to Czene et al. (2002) the factor E plays by far the most
important role for most cancer sites. These authors applied model
(27) to 15 common cancers. The genetic contribution to the variance
exceeded 0.5 only for the thyroid. For all other sites, σˆ2G was between
0.01 and 0.28 . Their estimated contributions to liability for lung and
colon cancer are given in Table 16. Their results are based on the
Swedish Family-Cancer Database, which contains more than 9.6 million
individuals. Similar results were reported in several related articles such
as Hemminki et al. (2001, 1998).
Site σˆ2G σˆ
2
S σˆ
2
F σˆ
2
E
Lung 0.08 (0.05-0.09) 0.09 (0.08-0.09) 0.04 (0.00-0.04) 0.79 (0.79-0.82)
Colon 0.13 (0.12-0.18) 0.12 (0.11-0.13) 0.06 (0.05-0.07) 0.69 (0.68-0.70)
Table 16: Estimated variance contributions (and 95% confidence intervals)
from the structural model (27) given in Czene et al. (2002).
The structural model outlined above can of course be criticized.
The assumptions of additivity, linearity and normality can be ques-
tioned. Confounding is also a major problem. It is for example not
so clear what the shared childhood environment factor F really mea-
sures. The genetic contribution G only accounts for additive genetic
effects. Interactions, gene-gene or gene-environment, will actually con-
tribute to F . It does not seem feasible to make proper inference on
140 CHAPTER 6. HETEROGENEITY
gene-environment interactions within this approach, since one had to
observe relatives over a range of known environmental settings. Also,
genetic resemblance between spouses is neglected. Therefore, Czene
et al. (2002) state that the heritable contribution G should be consid-
ered as a lower bound of the importance of genetic effects.
Even if we accept the model as it is, its interpretation remains diffi-
cult. The estimates in Table 16 show for example no significant shared
childhood environment effect for lung cancer. What does this mean?
The role of the specific childhood environment in lung cancer is contro-
versial. The main contribution to liability for lung cancer, the residual
environmental effect E , does not exclude exposure during childhood.
But it accounts solely for non-shared effects, that means individual,
sporadic causes, which can happen at any point in life. Finally, the re-
sults in Table 16 do not only contain biological information, they might
also be heavily influenced by the cultural and social standards of the
population studied.
6.5 Conclusion
The previous section has show that unknown environmental factors,
E , play a key role in cancer. Non-shared environmental effects mean
sporadic, eventually unique events, and they express the inherently
random part of carcinogenesis. Nevertheless, the progress in cancer
therapy shows that our understanding of cancer has grown rapidly over
the last decades. The short overview over some topics presented in
this chapter has shown various uses of statistical methods in cancer
research. The last two sections have illustrated in particular how diffi-
cult it is to extract relevant information from population based studies.
It is our conviction, that a mechanistic understanding - and therefore
mechanistic modeling - is crucial for a successful investigation of open
questions such as the interaction between genes and between genes and
environment. It is certainly interesting to work with the high through-
put methods from modern molecular biology, and the needed statistical
learning algorithms get more powerful. But such approaches should be
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used to elucidate well defined, clear cut problems. Blind applications
without detailed biological knowledge seem too optimistic. Statistics
can certainly contribute its part, but it should be brought in with a
modeling perspective in mind. This is supported by our impression
that many of the most relevant insights into cancer originate from clin-
ical research.
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